

PROF. DR. HASAN ŞENOL COŞKUN
ÖZGEÇMİŞ VE ESERLER LİSTESİ

Adı Soyadı: Prof Dr. Hasan Şenol Coşkun
Doğum Tarihi: 02 Aralık 1968

Öğrenim Durumu:			
Derece	Bölüm/Program	Üniversite	Yıl
Yüksek öğrenim öncesi	İlkokul: Isparta Yenişarbademli İlkokulu Ortaokul: Isparta Yenişarbademli ortaokulu Lise: Ankara Meteoroloji Teknik Lisesi		1975- 1987
Lisans	Tıp	Ege Üniversitesi	1993
Y. Lisans			
Tıpta Uzmanlık	İç Hastalığı	Ankara Üniversitesi	1998
Tıpta Yan Dal Uzmanlık	Tıbbi Onkoloji	Erciyes Üniversitesi	2002

Tıpta Uzmanlık Tezi Başlığı (özeti ekte) ve Danışman(lar)ı :		
Tez Alanı	Tez İsmi	Danışman
İç hastalıkları:	Multiple myeloma hastalarında serum transforming growth faktör beta düzeylerinin klinik ve prognoz ile ilişkisi. Danışman	Prof Dr Osman İlhan
Tıbbi Onkoloji	Meme Kanserinde Her2 Onkoprotein Ekspresyonu	Prof Dr Mustafa Altınbas

Görevler:		
Görev Unvanı	Akademik Görevler	Yıl
Dr. Ar.Gör.	Tıp Fakültesi Ankara Üniversitesi	1993-1998
Dr. Ar.Gör.	Tıp Fakültesi Erciyes Üniversitesi	1999-2001
Yar.Doç.Dr	Tıp Fakültesi Erciyes Üniversitesi	2001-2002
Yar.Doç.Dr	Tıp Fakültesi Süleyman Demirel Üniversitesi	2002-2005
Doç.Dr.	Tıp Fakültesi Süleyman Demirel Üniversitesi	2006-2007
Doç.Dr.	Tıp Fakültesi Akdeniz Üniversitesi	2007-2011
Prof Dr	Tıp Fakültesi Akdeniz Üniversitesi	2011-2022

Görev	Mesleki Deneyimler	Yıl
Asistan Dr	Tıp Fakültesi Ankara Üniversitesi	1993-1998
Asistan Dr	Tıp Fakültesi Erciyes Üniversitesi	1999-2001
Uzman Dr	Tıp Fakültesi Erciyes Üniversitesi	2001-2002
Uzman Dr	Tıp Fakültesi Süleyman Demirel Üniversitesi	2002-2007
Uzman Dr	Tıp Fakültesi Akdeniz Üniversitesi	2007-2022
Uzman Dr	Yaşam Hastaneler Grubu Yaşam Onkoloji Merkezi	2021-.....

Yönetilen Yüksek Lisans Tezleri :					
Yönetilen Doktora Tezleri/Sanatta Yeterlik Çalışmaları :					
Tez NO	Tez Öğrencisi	Tez ismi	Tez Alanı	Üniversite	Yıl
149276	NESİBE KARAKUŞ	İleri evre kanser hastalarında düşük molekül ağırlıklı heparin'in anjiyogenik faktörler üzerindeki etkisi	Tıpta Uzmanlık İç Hastalığı	Süleyman Demirel Üniversitesi	2006
308445	OZAN YILMAZ	Probiyotiklerin ratlarda Metotreksat toksisitesi üzerine olan etkileri	Tıpta Uzmanlık İç Hastalığı	Süleyman Demirel Üniversitesi	2008
446724	ALİ MURAT TATLI	Operate erken evre meme kanserinde adjuvan caf-dosetaksel ve cef-dosetaksel tedavilerinin karşılaştırılması...	Tıpta Uzmanlık Tıbbi Onkoloji	Akdeniz Üniversitesi	2012
10012212	SELDA UÇAR	A549 küçük hücre dışı akciğer kanseri hücre hattında daha önce etkinliği tanımlanmamış Türkiye ende...	Tezli Yüksek Lisans	Akdeniz Üniversitesi	2015
10014416	NİHAL GEÇİCİ	Kemoterapi alan opere meme kanseri hastalarında karakter ve mizaç özelliklerinin semptomlar ve yaşam...	Tıpta Uzmanlık İç Hastalığı	Akdeniz Üniversitesi	2013
10029794	FATİH SARGIN	Vücut yağ oranının kemoterapiye bağlı bulantı kusma üzerine etkisi	Tıpta Uzmanlık İç Hastalığı	Akdeniz Üniversitesi	2014
10141343	ZEHRA BOZTEPE	GBM (glioblastoma multiforme)tanılı, bevacizumab tedavisini alan hastalarda TP53 mutasyonu ve mgmt m...	Tezli Yüksek Lisans	Akdeniz Üniversitesi	2017
10142250	YASEMİN KONDAK	Oral kemoterapi kullanan hastalarda ilaç etkileşimleri riski ve risk düzeyinin uyku,yaşam kalitesine...	Tezli Yüksek Lisans	Akdeniz Üniversitesi	2017
10148355	SELİN KARKIN	Meme kanserinde adjuvan trastuzumab tedavisi alan hastalarda retrospektif etkinlik ve yan etki değer...	Tezli Yüksek Lisans	Akdeniz Üniversitesi	2017

1019118 7	ŞERİFE DİKİCİ	Solid kanserli hastalarda kemoterapi sonrası febril nötropeni riskinin nomogram ile retrospektif ana...	Tezli Yüksek Lisans	Akdeniz Üniversitesi	2018
1021320 6	TAHİR YERLİKAY A	18f-FDG PET/CT'de saptanan insidental tiroid lezyonların yönetim algoritması ve klinik önemi değerle...	Tıpta Uzmanlık İç Hastalığı	Akdeniz Üniversitesi	2018
1026112 4	MERVE SARI	Kanser hastalarında tromboz risk faktörleri ile beslenme parametreleri arasındaki ilişki	Tezli Yüksek Lisans	Akdeniz Üniversitesi	2019
1035572 6	HAKAN EMİNOĞL U	Metastazektomi uygulanan kanser hastalarının klinik özellikleri ve metastazektominin sağkalıma katkı...	Tıpta Uzmanlık İç Hastalığı	Akdeniz Üniversitesi	2020
1038154 1	HAYRİYE BAŞER	Pediyatrik hastalarda kalıcı santral venöz kateter eğitiminin komplikasyonlara etkisi	Tezli Yüksek Lisans	Akdeniz Üniversitesi	2021
1038239 3	ZELİHA KOCA	Port kateterli bevacizumab kullanan ve kullanmayan hastalarda semptomların retrospektif incelenmesi	Tezli Yüksek Lisans	Akdeniz Üniversitesi	2021
10429758	AYTAÇ TERZİ	Kolorektal Kanserde Adjuvan Kemoterapi Başlama Süresinin Sağkalıma Etkisi	Tıpta Uzmanlık İç Hastalığı	Akdeniz Üniversitesi	2021

Projelerde Yaptığı Görevler :

1-Metastatik renal cell karsinomlu hastalarda interleukin-2, interferon alfa ve 5-fluorourasil kemoimmunoterapisinin etkinliği. Erciyes Üniversitesi Araştırma Fonu Projesi, 00-011-32, **Yardımcı Araştırmacı**, 2000.

2-Metastatik malign melanom tanısı ile izlenen hastalarda kemoimmunoterapi uygulaması. Erciyes Üniversitesi Araştırma Fonu Projesi, 00-011-33, **Proje yürütücüsü**, 2000.

3-Erişkin hastalarda TTS-Fentanilin kansere bağlı ağrı üzerindeki etkinliğinin değerlendirilmesi- FEN-TUR-1. Çok Merkezli Çalışma. Erciyes Üniversitesi Tıp Fakültesi Etik Kurulu, 02-212, **Yardımcı Araştırmacı**, 2002.

4-Akciğer Kanseri Hastalarında GSTP1,GSTM1, K-ras ve P53 Mutasyonlarının Moleküler Yöntemlerle Tespiti. Araştırma Projeleri Yönetim Birimi. Münferit proje. Proje No: 03-M-763, **Proje Yürütücüsü**, 2003

5-Solid Maligniteli Hastalarda Hematolojik Sorunlar. SDU Araştırma Projeleri Yönetim Birimi Altyapı Projesi. Proje No:2004/97 **Proje Yürütücüsü**, 2004

6- Solid tümörlü hastalarda anemi; eritrosit süspansiyonu transfüzyonu ve yaşam kalitesi üzerine etkisi. SDÜ Tıp Fakültesi Etik Kurul No ve Tarih:09.02.2005-2/03 **Proje yürütücüsü**, 2005

25 TSG-2020-5225 Gdml Arařtırmacı Remisyonda meme kanseri hastaların bilgi gereksinimi ve destek ihtiyalarının belirlenmesi 07.01.2020
26.02.2021

3711 TYL-2018-3711 Y.Lisans Arařtırmacı KEMOTERAPİYE BAĐLI PERİFERİK NROPATİ GELİŐİMİNDE İNSLİN DİRENCİNİN ROL 30.05.2018
24.03.2020

3277 TDK-2018-3277 Doktora Arařtırmacı Sistemik Tedavi Uygulanan Kanserli Hastalarda Telefonla Yapılan Semptom Triyaj Protokolnn Semptom Ynetimine Yařam Kalitesine ve zBakım Gcne Etkisi 07.06.2018 24.03.2020

2769 TYL-2017-2769 Y.Lisans Arařtırmacı Ailesel meme kanseri olgularında BRCA1 ve BRCA2 dıŐı yatkınlık genlerinin yeni nesil dizileme ile analizi 09.11.2017 17.05.2019

1546 TTU-2016-1546 T.Uzmanlık Arařtırmacı AkciĐer adenokarsinomlarında ROS1 gen yeniden dzenlenmesinin Floresan InSitu Hibridizasyon (FISH) ve immunohistokimyasal yntemle arařtırılması 04.05.2016 14.07.2017

218 TYL-2015-218Y.Lisans Ynetici GBM (Glioblastoma Multiforme)tanılı, Bevacizumab tedavisini alan hastalarda TP53 mutasyonu ve MGMT metilasyonunun prediktif deĐerinin arařtırılması 06.05.2015 31.10.2016

7-Prof. Dr. Hasan Őenol COŐKUN, yrtclĐn Do. Dr. Hicran BEKTAŐ'ın yaptıĐı 113S924 numaralı ve "Sistemik Tedavi Uygulanan Kanserli Bireyler İin Online EĐitim Programı GeliŐtirilmesi Ve Programın EtkinliĐinin DeĐerlendirilmesi" baŐlıklı projede "Arařtırmacı" olarak yer almaktadır.

Akademik ve İdari Grevler :

Bilim Dalı BaŐkanı

Sleyman Demirel niversitesi Tıp Fakltesi İ Hastalıkları ABD Tıbbi Onkoloji BD
2004-2007

Bilim Dalı BaŐkanı

Akdeniz niverstesi Tıp Fakltesi İ Hastalıkları ABD Tıbbi Onkoloji BD, 2013-
2018

Uzmanlar Kurulu yeliĐi

Akdeniz niverstesi SaĐlık Bilimleri Enstits
2017-2021

Dergi EditrlĐ

Journal of Oncological Science
2019

Dergi EditrlĐ, Alan Editr

Akdeniz Tıp Dergisi
2018-2021

EĐitim Koordinasyon Kurul BaŐkanlıĐı

Akdeniz niverstesi Tıp Fakltesi
2012 -2015

EĐitim Koordinasyon Kurul yeliĐi

2015-2018

Tıpta Uzmanlık Kurulu Tıbbi Onkoloji TUKMOS BaŐkanlıĐı

2014-2018

Tıpta Uzmanlık Kurulu Tıbbi Onkoloji TUKMOS yeliĐi

2018-Halen

Bilimsel Kuruluşlara Üyelikler:

- 1-İç Hastalıkları Uzmanlık Derneği
- 2-Tıbbi Onkoloji Derneği
- 3-Türk Onkoloji Grubu (TOG) ve Onkoloji Grubu Derneği
- 4-Türk Hematoloji Derneği
- 5-European Society of Medical Oncology (ESMO)
- 6-American Society of Clinical Oncology (ASCO) (İnaktif)

Ödüller :

1: XXVII. Ulusal Hematoloji Kongresi, 11-13 Kasım 1999, İstanbul En iyi klinik çalışma ödülü.

Üstün C, İdilman R, Çelebi H, Akan H, Karayalçın S, Arslan Ö, Özcan M, Gürman G, Coşkun HŞ, Aktemel A, Arat M, Akçağlayan E, İlhan O, Beksaç M, Demirer T, Konuk N, Uysal A, Koç H. Hepatit B virus (HBV) ve HBV aşılmasının allojeneik periferik kök hücre transplantasyonu (APKHT) sonrası gelişen kraciğer komplikasyonlarına etkileri.

2: 1. Tıbbi Onkoloji Kongresi, 29 Mart – 2 nisan 2006, Antalya Sözel Bildiri Ödülü

Bülent Yalçın, Fazıl Aydın, Nurullah Zengin, Mahmut İlhan, Abdurrahman Işıkdoğan, Faruk Aykan, Gökhan Demir, Fikri İçli. Türkiye’de mide kanserli hastaların klinikopatolojik özellikleri: Çok merkezli retrospektif çalışma (TOG)

3: 2. Ulusal Onkolojik Araştırmalar Çalıştayı, 12-14 Ocak 2007. Ankara Bildiri Ödülü

Mustafa ÖZOğan, Hakan Bozcuk, Özlem Er, Hüseyin Abalı, Hasan Şenol Coşkun, urullah Zengin, Mustafa Samur. Türkiye’de Kanser Hastalarının Bilgi istekleri, yakınlarının bu konuya bakışı ve hasta-hasta yakını görüş farklılıklarında belirleyici faktörler: Çok merkezli çalışma.

4: 5th International Gastrointestinal Cancer Conference, 4-6 December 2015, İstanbul

Best Oral Presantaion Award 1St Place

Mehmet Artaç, Hasan Şenol Coşkun, Faysal Dane, Bülent Karabulut, Levent Korkmaz, Mustafa Karaağaç, Devrim Çabuk, Nuri Faruk Aykan, Hatice Doruk, N,lüfer Acvı, Nazım Serdar Tural. Chemotherapy plus bevacizumab combinations for fisrt-line treatment in metastatic colorectal cancer.

5: 4.Tıbbi Onkoloji Kongresi, 21-25 Mart 2012, Antalya.

Seçilmiş Sözel Bildiri Ödülü.

M.Uysal, H.Bozcuk, S.S.Goksu, A.M.Tatlı, D.Arslan, S.Gündüz, H.S.Coskun, M.Ozdogan, B.Savas. Bevacizumab İle Tedavi Edilen Metastatik Kolorektal Kanserli Hastalarda Prognostik Faktör Olarak Proteinüri.

6: 5. İmmunoterapi ve Onkoloji Kongresi 13-17 Ekim 2021, Antalya

Sözlü Bildiri Birincilik Ödülü.

Hasan Şenol Coşkun, Robert J Motzer, Nizar M TAnnir, David F Mcdermott, Mauricio Burotto, Toni K Chueiri, Hans J Hammers, Elizabeth R Plimack, Camillo Porta, Saby

George, Thomas Powles, Frede Donskov. İleri renal hücreli karsinomda (aRCC) birinci basamak nivolumab + ipilimumab (N+I) ve sunitibin (S) karşılaştırıldığı ChecMAte-214 çalışmasının koşullu sağkalım ve 5 yıllık takip sonuçları

Lisans ve lisansüstü düzeydeki verilen dersler

1-Lisans dersleri

Tıp fakültesi dönem 4 iç hastalıkları stajı
Onkolojinin klinik temelleri
Kanserde tedavi prensipleri
Kanserde sistemik tedaviler
Kanserde palyatif tedaviler
Akciğer kanseri
Onkolojik aciller ve febril nötropeni
Meme kanseri

2-Yüksek lisans dersleri

Onkolojik eğitim ve Klinik araştırma Yüksek Lisans
Kanser sistemik tedaviler
Kanser ve beslenme

KLİNİK ARAŞTIRMALAR

N	Study Code		Study Name	Status
1	1302.5	PI	A multicenter, randomized, double-blind Phase III trial to evaluate efficacy and safety of BI 695502 plus chemotherapy versus Avastin® plus chemotherapy in patients with advanced non-squamous Non-Small Cell Lung Cancer	Closed
2	B7391003	PI	A Phase 3 Randomized, Double-blind Study Of Pf-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel - Carboplatin For The First-line Treatment Of Patients With Advanced Non-squamous Non-small Cell Lung Cancer	Closed
3	MK-3475-057	PI	A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy	Closed
4	EMR100070-007	PI	A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro- esophageal junction	Closed
	I4D-MC-	PI	A Phase 3, Randomized, Double-Blind, Placebo Controlled	Closed

	JVDC		Study of Ramucirumab plus Docetaxel Versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy	
	I4D-MC-JTJH	PI	A Phase 2 Study of LY2606368 in patients with extensive stage disease small cell lung cancer	Closed
	I3Y-MC-JPBK	PI	A Randomized Phase 3 Study of Abemaciclib plus Supportive Care versus Erlotinib plus Best Supportive Care in Patient with Stage IV NSCLC with Detectable KRAS Mutation Who Have Progressed After Platinum Based-Chemotherapy	Closed
	I3O-MC-JSBF	PI	A Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo plus Cisplatin and Gemcitabine as First-Line Treatment in Patients with Advanced or Metastatic Biliary Tract Cancer	Closed
	I3Y-MC-JPCE	S I	A Phase 1b Study of Abemaciclib in Combination with Pembrolizumab for Patients with Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer	Closed
	M16-298	PI	A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU)	Closed
	CA209-714	S I	A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in Combination with Ipilimumab Placebo In Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	Closed
	I3Y-MC-JPCF	S I	A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer	Open
	M12-914	PI	A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer	Closed
	B701-U21	PI	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of B-701 Plus Docetaxel Versus Placebo Plus Docetaxel in the Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma in Subjects who have Relapsed After or A Refractory to Standard Therapy	Closed
	B701-U22	PI	A Multi-center ,Open-Label Phase 1b/2 Study of a Novel FGFR3 Inhibitor (B701) Combined with Pembrolizumab in Subjects with Locally Advanced or Metastatic Urothelial Carcinoma who have Progressed Following Platinum-based Chemotherapy	Closed
	CA209-649	PI	A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer	Open
	CA209-817	PI	Phase IIIB/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with non-small cell lung cancer	Open
	MK3475-654	S I	A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epcadostat (INCB024360) Versus	Closed

			Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1	
MK3475-698	PI		A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease	Closed
CA209-9ER	PI		A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma	Open
MK3475-826	PI		A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE826)	Open
PACIFIC 2	PI		A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently with Platinum-based Chemoradiation Therapy in Patients with Locally Advanced, Unresectable Non-small Cell Lung Cancer (Stage III)	Open
CAPISCO	SI		A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing The Efficacy And Safety Of Targeted Therapy Or Cancer Immunotherapy Guided By Genomic Profiling Versus Platinum-Based Chemotherapy In Patients With Cancer Of Unknown Primary Site Who Have Received Three Cycles Of Platinum Doublet Chemotherapy	Open
BP40234	SI		An Open-Label, Multicenter, Phase II Study To Evaluate The Therapeutic Activity Of RO6874281, An Immunocytokine, Consisting Of Interleukin-2 Variant (Il-2v) Targeting Fibroblast Activation Protein-A (Fap), In Combination With Atezolizumab (Anti-Pd-L1), Administered Intravenously, In Participants With Advanced And/Or Metastatic Solid Tumors	Open
13Y-MC-JPCP	SI		A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer	Closed
MK7339-001	SI		A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43)	Open
MK7902-007	SI		A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without Lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007)	Closed
MK7902-001	SI		A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)	Open
MK7902-002	PI		A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination with	Closed

			Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma (LEAP-002)	
M14-294	PI		Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer	Closed
ADRIATIC	PI		Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)	Open
BFAST	SI		A Phase II/III Multicenter Study Evaluating The Efficacy and Safety Of Multiple Targeted Therapies As Treatments For Patients With Advanced Or Metastatic Non Small Cell Lung Cancer Harboring Actionable Somatic Mutations Detected In Blood	Open
RIGHT CHOICE	SI		Study to the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer	Open
6409174 2PCR300 1	PI		A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer	Open
PROSELI CA	PI		Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m ²) and the Currently Approved Dose (25 mg/m ²) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer	Closed
PERUSE	PI		Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer	Closed
HANNAH	SI		A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer	Closed
POPLAR	SI		A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy	Closed
JACOP	SI		A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer (JACOB)	Closed
SAFEHER	PI		A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer	Closed
Lux-lung 8	PI		LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy	Closed
(LUME- Colon 1)	PI		Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer	Closed
M11-089	PI		Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer	Closed
EMR100	PI		Avelumab in First-line NSCLC (JAVELIN Lung 100)	Closed

	070-005			
	MK7339-002	S I	Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)	Open
	MK7339-007	S I	Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)	Open
	8951-CL-0302	PI	A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma	Open
	CLEE011 A3201C	S I	Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer	Open
	BGB-A317-305	PI	Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma	Open
	JTX-4014-202	PI	Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen	Open
	CA209-7FL	S I	Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer	Open
	SAMSON 2	PI	A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients	Open
	CAPITEL LO	PI	Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency	Open
	J2J-OX-JZLC	S I	Study of LY3484356 Versus Hormone Therapy, in Participants With Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer (EMBER-3)	Open
	EFC1593 5	S I	Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer	Open
	MK3475-B49	S I	Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)	Open
	Nutide-121	PI	A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer	Open
	DZB-CS-202	PI	A Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations (FIDES-	Open

		03)		
DS8201-AU-301	PI	Clinical Study Protocol A Phase 3, Multicenter, Randomized, Open Label, Active-Controlled Study Of Trastuzumab Deruxtecan (Ds-8201a), An Anti Her2-Antibody Drug Conjugate, Versus Treatment Of Investigator's Choice For Her2-Positive, Unresectable And/Or Metastatic Breast Cancer Subjects Previously Treated With T-Dm1		Open

YAYINLAR VE ATIFLAR

Web Of Science

24/01/2022

<https://www.webofscience.com/wos/woscc/citation-report/79080049-7b10-4b4a-bc99-7f192df9a2a2-206d4d62>

H İndex: 14

Total yayın: 173

Total atif: 1148

Ortalama yayın başına atif: 6.64

Google Akademik

24/01/2022

https://scholar.google.com.tr/citations?hl=tr&user=3VmVsWgAAAAJ&pagesize=100&sortBy=pubdate&scilu=&scisig=AMD79ooAAAAAYfEAIL75rBQvIqncH3f20OXIU971g07&gmla=AJsN-F6yO2XWgcn76_hY_djc-e0DPY-12PFc2wUMBFEDotMVZu37mzznXeMS8a8zMe2u4cCrTc-GABdE8glyYS8tcz5i122Gm9452aM_U099rCIB4oT9hWpjOqM3bkBKEhxD6GrW9CuL&sciun d=12521400530413844022

H indexi:21

İ10 indeksi: 48

Yayın: 324

Atif: 2154

PubMED

24/01/2022

<https://pubmed.ncbi.nlm.nih.gov/?term=coskun+hs&sort=date&size=200>

Yayın: 112

ESERLER

A.Uluslararası hakemli dergilerde yayımlanan makaleler (SCI ve SCI Expanded):

1: Ustün C, Arslan O, Beksaç M, Koç H, Gürman G, Özçelik T, Yılmaz B, İlhan O, Akan H, Özcan M, Demirer T, Uysal A, Konuk N, Arat M, Dilek I, Celebi H, Coskun HS. A retrospective comparison of allogeneic peripheral blood stem cell and bone

- marrow transplantation results from a single center: a focus on the incidence of graft-vs.-host disease and relapse. *Biol Blood Marrow Transplant.* 1999;5(1):28-35. doi: 10.1053/bbmt.1999.v5.pm10232738. PMID: 10232738.
- 2: Çelebi H, Üstün C, Arat M, Akan H, Tunçman G, Özçelik T, Coşkun HŞ, Koç H. An Extra Benefit of Allogeneic Peripheral Blood Stem Cell Transplantation in a Patient with Lymphoblastic Lymphoma: Cure of Thalassemia Minor. *Turk J Haematol.* 2000 Jun 5;16(4):77-9. PMID: 27265858.
- 3: Er O, Coşkun HS, Altınbaş M, Akgün H, Cetin M, Eser B, Unal A. Rapidly relapsing squamous cell carcinoma of the renal pelvis associated with paraneoplastic syndromes of leukocytosis, thrombocytosis and hypercalcemia. *Urol Int.* 2001;67(2):175-7. doi: 10.1159/000050980. PMID: 11490218.
- 4: Eser B, Cetin M, Kontas O, Unal A, Er O, Coskun HS, Altinbas M. Facial nerve paralysis and paraplegia as presenting symptoms of acute myeloid leukemia. *Jpn J Clin Oncol.* 2001 Feb;31(2):86-8. doi: 10.1093/jjco/hye013. PMID: 11302348.
- 5: Cetin M, Eser B, Er O, Unal A, Kilic E, Patiroglu T, Coskun HS, Altinbas M, Arslan D, Ilhan O. Effects of DMSO on platelet functions and P-selectin expression during storage. *Transfus Apher Sci.* 2001 Jun;24(3):261-7. doi: 10.1016/s1473-0502(01)00068-4. PMID: 11791701.
- 6: Coşkun HŞ, Eser B, Çetin M, Er Ö, Ünal A, Altınbaş M, Karahacıoğlu E, Kaplan B. Hodgkin's Disease: Results of a Single Center in Central Anatolia. *Turk J Haematol.* 2001 Jun 5;18(2):117-22. PMID: 27264066.
- 7: Arslan Ö, Coşkun HŞ, Arat M, Soydan E, Özcan M, Gürman G, Çelebi H, Demirer T, Akan H, İlhan O, Konuk N, Uysal A, Berksaç M, Koç H. The Role of ABO Incompatibility in Allogeneic Peripheral Blood Stem Cell Transplant. *Turk J Haematol.* 2002 Sep 5;19(3):401-9. PMID: 27264977.
- 8: Coşkun HŞ, Er Ö, Tanrıverdi F, Altınbaş M. Hypereosinophilia as a Preclinical Sign of Tongue Squamous Cell Cancer in a Gastric Cancer Patient with Complete Remission. *Turk J Haematol.* 2003 Jun 5;20(2):107-10. English. PMID: 27265441.
- 9: Altinbas M, Er O, Ozkan M, Coskun HS, Gulmez I, Ekici E, Kaplan B, Eser B, Ozesmi M. Ifosfamide, mesna, and interferon-alpha2A combination chemoimmunotherapy in malignant mesothelioma: results of a single center in central anatolia. *Med Oncol.* 2004;21(4):359-66. doi: 10.1385/MO:21:4:359. PMID: 15579920.
- 10: Er O, Coskun HS, Altinbas M, Ozkan M, Eser B, Cetin M, Altuntas F, Unal A. Meropenem +/- granulocyte colony stimulating factor in the treatment of febrile neutropenic patients with cancer: prospective randomized study. *J Chemother.* 2004 Jun;16(3):288-92. doi: 10.1179/joc.2004.16.3.288. PMID: 15330327.
- 11: Ozkan M, Altinbas M, Er O, Kaplan B, Coskun HS, Karahacioglu E, Menku A, Cihan Y, Kontas O, Akdemir H. Post-operative sequential chemo-radiotherapy in high-grade cerebral gliomas with fotemustine. *J Chemother.* 2004 Jun;16(3):298-302. doi: 10.1179/joc.2004.16.3.298. PMID: 15330329.
- 12: Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, Cetin M, Soyuer S. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. *J Thromb Haemost.* 2004

- Aug;2(8):1266-71. doi: 10.1111/j.1538-7836.2004.00871.x. PMID: 15304029.
- 13: Coskun HS, Er O, Soyuer S, Altinbas M, Eser B, Karahacioglu E, Altuntas F. Solitary plasmacytoma: experiences from Central Anatolia. *Ir J Med Sci.* 2005 Jan-Mar;174(1):33-6. doi: 10.1007/BF03168516. PMID: 15868887.
- 14: Altinbas M, Er O, Ozkan M, Solak Y, Coskun HS, Kucuk C, Gursoy S. Irinotecan plus cisplatin combination against metastatic gastric cancer: phase II study. *Med Oncol.* 2005;22(2):153-60. doi: 10.1385/MO:22:2:153. PMID: 15965278.
- 15: Arslan Ç, Coşkun HŞ. Thrombocytosis in solid tumors: review of the literature. *Turk J Haematol.* 2005 Jun 5;22(2):59-64. PMID: 27264662.
- 16: Coşkun HŞ, İlhan O, Özcan M, Ayaz S, Dalva K, Üstün C, Arat M. Serum transforming growth factor beta 1 levels in multiple myeloma patients. *Turk J Haematol.* 2006 Mar 5;23(1):47-52. English. PMID: 27265228.
- 17: Koroglu M, Koroglu BK, Akhan O, Coskun HS, Yildizz H, Yesildag A, Oyar O. Effect of percutaneous biliary drainage on serum levels of tumor markers in patients with obstructive jaundice. *Hepatogastroenterology.* 2006 Jul-Aug;53(70):491-6. PMID: 16995447.
- 18: Coskun HS, Ozbalci D, Sahin M. An unusual side-effect of tramadol: subcutaneous nodules. *J Eur Acad Dermatol Venereol.* 2006 Sep;20(8):1008-9. doi: 10.1111/j.1468-3083.2006.01599.x. PMID: 16922958.
- 19: Canoz O, Ozkan M, Arsav V, Er O, Coskun HS, Soyuer S, Altinbas M. The role of c-erbB-2 expression on the survival of patients with small-cell lung cancer. *Lung.* 2006 Sep-Oct;184(5):267-72. doi: 10.1007/s00408-005-2591-y. PMID: 17235726.
- 20: Eser B, Altuntas F, Soyuer I, Er O, Canoz O, Coskun HS, Cetin M, Unal A. Acute lymphoblastic leukemia associated with brucellosis in two patients with fever and pancytopenia. *Yonsei Med J.* 2006 Oct 31;47(5):741-4. doi: 10.3349/ymj.2006.47.5.741. PMID: 17066520; PMCID: PMC2687762.
- 21: Sahin M, Keskin M, Tunc SE, Coskun HS, Kapucuoglu N. Kaposi's sarcoma complicating rheumatoid arthritis treated with corticosteroid Kaposi's sarcoma and rheumatoid arthritis. *Saudi Med J.* 2007 Jul;28(7):1133-4. PMID: 17603728.
- 22: Coşkun HS, Göksu SS, Sahin M, Alanoğlu G. Bleomycin, etoposide and cisplatin (BEP) combination with concurrent imatinib mesylate (GLEEVEC) in chronic myeloid leukemia (CML) patient with mesenchymal tumor. *Med Oncol.* 2008;25(1):110-2. doi: 10.1007/s12032-007-0053-5. Epub 2007 Aug 21. PMID: 18188725.
- 23: Coşkun HŞ, Kargı A, Özdoğan M, Bozcuk H, Savaş B. Leukocytosis, thrombocytosis and hypercalcemia as a triple paraneoplastic syndrome in a patient with squamous cell carcinoma of the renal pelvis. *Turk J Haematol.* 2010 Mar 5;27(1):51-2. English. PMID: 27265802.
- 24: Dogan M, Dogan L, Ozdemir F, Ozdemir NY, Coskun HS, Arslan UY, Ozal G, Utkan G, Demirkazik A, Aydin F, Zengin N, Icli F. Fifty-one Kaposi sarcoma patients. *Clin Transl Oncol.* 2010 Sep;12(9):629-33. doi: 10.1007/s12094-010-0568-7. PMID: 20851804.

- 25: Coşkun HŞ, Coşkun D, Durak S, Aydın S, Yıldız M. Specialist physicians should be aware of the national cancer control and screening program: a report from medical oncologists in Turkey. *Asian Pac J Cancer Prev.* 2011;12(1):337. PMID: 21517283.
- 26: Tatli AM, Uysal M, Goksu SS, Arslan D, Gunduz S, Ozdogan M, Coskun HS, Bozcuk H, Savas B. Primary mucinous adenocarcinoma of the bladder: complete response with FOLFOX-4 regimen. *Med Oncol.* 2012 Sep;29(3):1935-7. doi: 10.1007/s12032-011-0090-y. Epub 2011 Oct 30. PMID: 22042507.
- 27: Ürün Y, Utkan G, Yalcin Ş, Coşkun HŞ, Koçer M, Özdemir NY, Kaplan MA, Arslan ÜY, Özdemir F, Öztuna D, Akbulut H, İçli F. Lack of any relationship between ABO and Rh blood groups and clinicopathological features in patients with gastrointestinal stromal tumors: Turkish Oncology Group. *Asian Pac J Cancer Prev.* 2012;13(8):4129-31. PMID: 23098529.
- 28: Gunduz S, Elpek GO, Uysal M, Goksu SS, Tatli M, Arslan D, Coskun HS, Bozcuk H, Savas B, Ozdogan M. Coexistence of gastric adenocarcinoma and choriocarcinoma: complete response to trastuzumab and chemotherapy. *Case Rep Oncol.* 2012 May;5(2):394-9. doi: 10.1159/000341662. Epub 2012 Jul 24. PMID: 23525369; PMCID: PMC3409517.
- 29: Uysal M, Goksu SS, Coskun HS, Savas B, Ozdogan M, Bozcuk H. Intraarticular hemorrhage due to bevacizumab in a patient with metastatic colorectal cancer: a case report. *J Med Case Rep.* 2012 Jul 9;6:188. doi: 10.1186/1752-1947-6-188. PMID: 22776219; PMCID: PMC3464779.
- 30: Arslan D, Gündüz S, Tural D, Uysal M, Tatlı AM, Başsorgun Cİ, Elpek GÖ, Coşkun HŞ, Bozcuk HŞ, Savaş B. Inflammatory myofibroblastic tumor: a rarely seen submucosal lesion of the stomach. *Case Rep Oncol Med.* 2013;2013:328108. doi: 10.1155/2013/328108. Epub 2013 Mar 19. PMID: 23573435; PMCID: PMC3615588.
- 31: Urun Y, Utkan G, Cangir AK, Oksuzoglu OB, Ozdemir N, Oztuna DG, Kocaman G, Coşkun HŞ, Kaplan MA, Yuksel C, Demirkazik A, Icli F. Association of ABO blood group and risk of lung cancer in a multicenter study in Turkey. *Asian Pac J Cancer Prev.* 2013;14(5):2801-3. doi: 10.7314/apjcp.2013.14.5.2801. PMID: 23803034.
- 32: Tatlı AM, Gunduz S, Göksu SS, Arslan D, Uysal M, Başsorgun Cİ, Coşkun HŞ. Dystrophic Cutaneous Calcification and Metaplastic Bone Formation due to Long Term Bisphosphonate Use in Breast Cancer. *Case Rep Oncol Med.* 2013;2013:871917. doi: 10.1155/2013/871917. Epub 2013 Jul 15. PMID: 23956898; PMCID: PMC3728502.
- 33: Uysal M, Bozcuk H, Karakilinc H, Goksu S, Tatli AM, Gunduz S, Arslan D, Coskun HS, Savas B. Pesticides and cancer: the first incidence study conducted in Turkey. *J Environ Pathol Toxicol Oncol.* 2013;32(3):245-9. doi: 10.1615/jenvironpatholtoxicoloncol.2013008232. PMID: 24266411.
- 34: Sezgin Göksu S, Bilal S, Coşkun HŞ. Hepatitis B reactivation related to everolimus. *World J Hepatol.* 2013 Jan 27;5(1):43-5. doi: 10.4254/wjh.v5.i1.43. PMID: 23383366; PMCID: PMC3562726.
- 35: Kargi A, Uysal M, Bozcuk H, Coskun HS, Savas B, Ozdogan M. The importance of COX-2 expression as prognostic factor in early breast cancer. *J BUON.* 2013 Jul-Sep;18(3):579-84. PMID: 24065467.

- 36: Arslan D, Avci F, Merdin A, Gunduz S, Coskun HS. Management of a patient with colon cancer and rotor syndrome: A case report. *Oncol Lett.* 2014 Mar;7(3):797-798. doi: 10.3892/ol.2013.1766. Epub 2013 Dec 19. PMID: 24520296; PMCID: PMC3919936.
- 37: Arslan D, Bozcuk H, Gunduz S, Tural D, Tattli AM, Uysal M, Goksu SS, Bassorgun Cİ, Koral L, Coskun HS, Ozdogan M, Savas B. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system. *Asian Pac J Cancer Prev.* 2014;15(6):2465-72. doi: 10.7314/apjcp.2014.15.6.2465. PMID: 24761848.
- 38: Gunduz S, Mutlu H, Uysal M, Coskun HS, Bozcuk H. Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors. *Asian Pac J Cancer Prev.* 2014;15(8):3801-4. doi: 10.7314/apjcp.2014.15.8.3801. PMID: 24870797.
- 39: Goksu SS, Gunduz S, Unal D, Uysal M, Arslan D, Tatli AM, Bozcuk H, Ozdogan M, Coskun HS. Use of blood transfusion at the end of life: does it have any effects on survival of cancer patients? *Asian Pac J Cancer Prev.* 2014;15(10):4251-4. doi: 10.7314/apjcp.2014.15.10.4251. PMID: 24935379.
- 40: Arslan D, Uysal M, Tatlı AM, Gunduz S, Goksu SS, Başsorgun Cİ, Coskun HS, Bozcuk H, Savaş B. Her-2 positive gastric cancer presented with thrombocytopenia and skin involvement: a case report. *Case Rep Oncol Med.* 2014;2014:194636. doi: 10.1155/2014/194636. Epub 2014 Jun 23. PMID: 25045559; PMCID: PMC4090488.
- 41: Goksu SS, Tastekin D, Arslan D, Gunduz S, Tatli AM, Unal D, Salim D, Guler T, Coskun HS. Clinicopathologic features and molecular subtypes of breast cancer in young women (age ≤35). *Asian Pac J Cancer Prev.* 2014;15(16):6665-8. doi: 10.7314/apjcp.2014.15.16.6665. PMID: 25169505.
- 42: Tatlı AM, Coşkun HŞ, Uysal M, Arslan D, Sezgin Göksu S, Güenay Gündüz S, Cakal S, Bozcuk HŞ, Savaş B. Treatment with capecitabine + bevacizumab following induction treatment with FOLFIRI + bevacizumab in metastatic colorectal carcinoma. *Int J Clin Exp Med.* 2014 Aug 15;7(8):2191-6. PMID: 25232406; PMCID: PMC4161566.
- 43: Eryilmaz MK, Mutlu H, Salim DK, Musri FY, Tural D, Coskun HS. The neutrophil to lymphocyte ratio has a high negative predictive value for pathologic complete response in locally advanced breast cancer patients receiving neoadjuvant chemotherapy. *Asian Pac J Cancer Prev.* 2014;15(18):7737-40. doi: 10.7314/apjcp.2014.15.18.7737. PMID: 25292055.
- 44: Gunduz S, Mutlu H, Goksu SS, Arslan D, Tatli AM, Uysal M, Coskun HS, Bozcuk H, Ozdogan M, Savas B. Oral cyclophosphamide and etoposide in treatment of malignant pleural mesothelioma. *Asian Pac J Cancer Prev.* 2014;15(20):8843-6. doi: 10.7314/apjcp.2014.15.20.8843. PMID: 25374217.
- 45: Goksu SS, Bozcuk H, Uysal M, Ulukal E, Ay S, Karasu G, Soydas T, Coskun HS, Ozdogan M, Savas B. Determinants of opioid efficiency in cancer pain: a comprehensive multivariate analysis from a tertiary cancer centre. *Asian Pac J Cancer Prev.* 2014;15(21):9301-5. doi: 10.7314/apjcp.2014.15.21.9301. PMID: 25422216.

- 46: Salim DK, Mutlu H, Eryilmaz MK, Musri FY, Tural D, Gunduz S, Coskun HS. Molecular types and neoadjuvant chemotherapy in patients with breast cancer-while molecular shifting is more common in luminal a tumors, the pathologic complete response is most frequently observed in her-2 like tumors. *Asian Pac J Cancer Prev.* 2014;15(21):9379-83. doi: 10.7314/apjcp.2014.15.21.9379. PMID: 25422228.
- 47: Sezgin Goksu S, Gunduz S, Unal D, Uysal M, Arslan D, Tatlı AM, Bozcuk H, Ozdogan M, Coskun HS. Use of chemotherapy at the end of life in Turkey. *BMC Palliat Care.* 2014 Nov 19;13(1):51. doi: 10.1186/1472-684X-13-51. PMID: 25435808; PMCID: PMC4247666.
- 48: Mutlu H, Arslan D, Gündüz S, Tural D, Büyükçelik A, Cihan YB, Aslan T, Bozcuk H, Coşkun HS. The Optimal Treatment Modality in Patients with T4N2M0 Non-Small Cell Lung Cancer: The Best Choice May Be Definitive Chemoradiotherapy Followed by Consolidation Chemotherapy. *Chemotherapy.* 2014;60(2):107-11. doi: 10.1159/000371414. PMID: 25721008.
- 49: Gunduz S, Coskun HS, Arslan D, Goksu SS, Tatli AM, Uysal M, Ozdogan M, Savas B. Can positron emission tomography-computed tomography predict response in locally advanced rectal cancer patients treated with induction folinic acid and 5-flourouracil? *Indian J Cancer.* 2014 Apr-Jun;51(2):138-41. doi: 10.4103/0019-509X.138234. PMID: 25104195.
- 50: Mutlu H, Coşkun HŞ. Is there any cumulative dose for trastuzumab? *J Oncol Pharm Pract.* 2015 Dec;21(6):468-70. doi: 10.1177/1078155214538686. Epub 2014 Jun 5. PMID: 24903272.
- 51: Mutlu H, Gündüz S, Büyükçelik A, Yıldız O, Uysal M, Tural D, Bozcuk H, Coşkun HŞ. The necessity of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma using antiangiogenic targeted therapy after interferon alfa-2b. *Clin Genitourin Cancer.* 2014 Dec;12(6):447-50. doi: 10.1016/j.clgc.2014.06.006. Epub 2014 Jun 8. PMID: 25022784.
- 52: Mutlu H, Gündüz S, Karaca H, Büyükçelik A, Cihan YB, Erden A, Akca Z, Coşkun HS. Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study. *Med Oncol.* 2014 Aug;31(8):74. doi: 10.1007/s12032-014-0074-9. Epub 2014 Jun 24. PMID: 24958517.
- 53: Göksu SS, Göksu UA, Gündüz S, Coskun HS. Rising CEA levels in a patient with colon carcinoma: metachronous medullary thyroid cancer. *Int J Biol Markers.* 2014 Jun 25;29(2):e184-6. doi: 10.5301/jbm.5000066. PMID: 24425322.
- 54: Altinbas M, Dikilitas M, Ozkan M, Dogu GG, Er O, Coskun HS. The effect of small-molecular-weight heparin added to chemotherapy on survival in small-cell lung cancer - A retrospective analysis. *Indian J Cancer.* 2014 July-September;51(3):324-329. doi: 10.4103/0019-509X.146784. PMID: 25494131.
- 55: Gunduz S, Ozgur O, Bozcuk H, Coşkun HS, Ozdogan M, Erkilic M, Sindel T, Yildiz A, Yilmaz S, Boz A, Aydin F, Karayalçin B, Savas B. Yttrium-90 radioembolization in patients with unresectable liver metastases: determining the factors that lead to treatment efficacy. *Hepatogastroenterology.* 2014 Sep;61(134):1529-34. PMID: 25436337.

56: Gunduz S, Mutlu H, Uysal M, Coskun HS, Bozcuk H. Elucidating the correlation between treatment with tyrosine kinase inhibitors and mean platelet volume in patients with metastatic renal cell cancer. *Oncol Lett.* 2014 Nov;8(5):2249-2252. doi: 10.3892/ol.2014.2495. Epub 2014 Sep 3. PMID: 25289104; PMCID: PMC4186555.

57: Kivrak Salim D, Mutlu H, Karakurt Eryilmaz M, Yalçın Musri F, Tural D, Coşkun HŞ. Metronomic maintenance chemotherapy in patients presenting with paraneoplastic autoimmune hepatitis with recurrent thymic carcinoma. *J Oncol Pharm Pract.* 2016 Apr;22(2):313-5. doi: 10.1177/1078155214551318. Epub 2014 Sep 16. PMID: 25231462.

58: Türker İ, Kömürcü Ş, Arıcan A, Doruk H, Özyılkan Ö, Coşkun HŞ, Colak D, Üçgül Çavuşoğlu E, Ata A, Sezer A, Yeşil Çinkır H, Şenler FC, Arpacı F. Investigational tests and treatments performed in terminal stage cancer patients in two weeks before death: Turkish oncology group (TOG) study. *Med Oncol.* 2014 Dec;31(12):350. doi: 10.1007/s12032-014-0350-8. Epub 2014 Nov 21. PMID: 25412940.

59: Bozcuk H, Yıldız M, Artaç M, Kocer M, Kaya Ç, Ulukal E, Ay S, Kılıç MP, Şimşek EH, Kılıçkaya P, Uçar S, Coskun HS, Savas B. A prospectively validated nomogram for predicting the risk of chemotherapy-induced febrile neutropenia: a multicenter study. *Support Care Cancer.* 2015 Jun;23(6):1759-67. doi: 10.1007/s00520-014-2531-6. Epub 2014 Nov 30. PMID: 25433439.

60: Benekli M, Yalcin S, Ozkan M, Elkiran ET, Sevinc A, Cabuk D, Coskun HS, Oksuzoglu B, Bayar B, Akbulat A, Ozet A. Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population. *Onco Targets Ther.* 2014 Dec 15;8:1-5. doi: 10.2147/OTT.S70670. PMID: 25548522; PMCID: PMC4271783.

61: Ulas A, Silay K, Akinci S, Dede DS, Akinci MB, Sendur MA, Cubukcu E, Coskun HS, Degirmenci M, Utkan G, Ozdemir N, Isikdogan A, Buyukcelik A, Inanc M, Bilici A, Odabasi H, Cihan S, Avci N, Yalcin B. Medication errors in chemotherapy preparation and administration: a survey conducted among oncology nurses in Turkey. *Asian Pac J Cancer Prev.* 2015;16(5):1699-705. doi: 10.7314/apjcp.2015.16.5.1699. PMID: 25773812.

62: Yalçın A, Silay K, Büyükçelik A, Işıkdoğan A, Türk HM, Coşkun HŞ, Özdemir F, Uğurlu M, Üstü Y, Yalçın B. Opinions of the Turkish population on cancer and being informed of the diagnosis of cancer. *Turk J Med Sci.* 2015;45(2):387-92. doi: 10.3906/sag-1312-72. PMID: 26084131.

63: Eryilmaz MK, Mutlu H, Salim DK, Musri FY, Tural D, Başsorgun I, Coşkun HŞ. Ipilimumab may increase the severity of cutaneous toxicity related to radiotherapy. *J Oncol Pharm Pract.* 2016 Jun;22(3):533-6. doi: 10.1177/1078155215572930. Epub 2015 Feb 17. PMID: 25694346.

64: Tatli AM, Besen AA, Kalender ME, Uysal M, Aslan D, Goksu SS, Gunduz SG, Coskun HS. Association of vitiligo and response in patients with metastatic malignant melanoma on temozolomide. *Tumori.* 2015 Mar-Apr;101(2):e67-9. doi: 10.5301/je.5000253. PMID: 25702668.

65: Gunduz S, Mutlu H, Tural D, Yıldız Ö, Uysal M, Coskun HS, Bozcuk H. Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer. *Asia Pac J Clin Oncol.* 2015 Dec;11(4):288-92. doi: 10.1111/ajco.12358.

Epub 2015 Apr 14. PMID: 25871569.

66: Salim DK, Mutlu H, Eryilmaz MK, Salim O, Musri FY, Tural D, Gündüz Ş, Coşkun HŞ. Neutrophil to lymphocyte ratio is an independent prognostic factor in patients with recurrent or metastatic head and neck squamous cell cancer. *Mol Clin Oncol*. 2015 Jul;3(4):839-842. doi: 10.3892/mco.2015.557. Epub 2015 May 4. PMID: 26171192; PMCID: PMC4486905.

67: Gündüz S, Göksu SS, Arslan D, Tatlı AM, Uysal M, Gündüz UR, Sevinç MM, Coşkun HS, Bozcuk H, Mutlu H, Savas B. Factors affecting disease-free survival in patients with human epidermal growth factor receptor 2-positive breast cancer who receive adjuvant trastuzumab. *Mol Clin Oncol*. 2015 Sep;3(5):1109-1112. doi: 10.3892/mco.2015.610. Epub 2015 Jul 21. PMID: 26623060; PMCID: PMC4534854.

68: Tatlı AM, Arslan D, Uysal M, Goksu SS, Gunduz SG, Coskun HS, Ozdogan M, Savas B, Bozcuk HS. Retrospective analysis of third-line chemotherapy in advanced non-small cell lung cancer. *J Cancer Res Ther*. 2015 Oct-Dec;11(4):805-9. doi: 10.4103/0973-1482.146092. PMID: 26881522.

69: Müsri FY, Mutlu H, Eryılmaz MK, Salim DK, Coşkun HŞ. Experience of bevacizumab in a patient with colorectal cancer after renal transplantation. *J Cancer Res Ther*. 2015 Oct-Dec;11(4):1018-20. doi: 10.4103/0973-1482.168996. PMID: 26881574.

70: Mutlu H, Balkarlı H, Musri FY, Salim DK, Eryılmaz MK, Ünal B, Coşkun HŞ. Gastrointestinal stromal tumor and isolated anterior tibial muscle metastasis as first recurrence. *J Cancer Res Ther*. 2015 Oct-Dec;11(4):1037. doi: 10.4103/0973-1482.151862. PMID: 26881647.

71: Göksu SS, Bozcuk H, Koral L, Çakar B, Gündüz S, Tatlı AM, Arslan D, Uysal M, Koçer M, Artaç M, Karabulut B, Coşkun HS, Özdoğan M, Savaş B. Factors predicting lapatinib efficacy in HER-2+ metastatic breast carcinoma: Does it work better in different histologic subtypes? *Indian J Cancer*. 2015 Oct-Dec;52(4):517-9. doi: 10.4103/0019-509X.178382. PMID: 26960462.

72: Gunduz S, Bozcuk H, Yıldız M, Goksu SS, Uysal M, Arslan D, Tatlı AM, Mutlu H, Coşkun HS, Ozdogan M. Line of abiraterone acetate in castration-resistant metastatic prostate cancer--Does it matter? report of a multi-institutional experience. *Indian J Cancer*. 2015 Oct-Dec;52(4):658-60. doi: 10.4103/0019-509X.178379. PMID: 26960509.

73: Eryılmaz MK, Mutlu H, Salim DK, Musri FY, Coşkun HŞ. Fatal posterior reversible leukoencephalopathy syndrome associated coma induced by bevacizumab in metastatic colorectal cancer and review of literature. *J Oncol Pharm Pract*. 2016 Dec;22(6):806-810. doi: 10.1177/1078155215611048. Epub 2015 Oct 13. PMID: 26467267.

74: Musri FY, Mutlu H, Eryılmaz MK, Salim DK, Gunduz S, Coskun HS. The Neutrophil to Lymphocyte Ratio is an Independent Prognostic Factor in Patients with Metastatic Gastric Cancer. *Asian Pac J Cancer Prev*. 2016;17(3):1309-12. doi: 10.7314/apjcp.2016.17.3.1309. PMID: 27039764.

75: Mutlu H, Eryılmaz MK, Musri FY, Gunduz S, Salim DK, Coskun HS. Mean Platelet Volume as an Independent Predictive Marker for Pathologic Complete Response after Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer.

Asian Pac J Cancer Prev. 2016;17(4):2089-92. doi: 10.7314/apjcp.2016.17.4.2089. PMID: 27221900.

76: Merdin A, Merdin FA, Gündüz Ş, Bozcuk H, Coşkun HŞ. Opioid endocrinopathy: A clinical problem in patients with cancer pain. *Exp Ther Med*. 2016 May;11(5):1819-1822. doi: 10.3892/etm.2016.3156. Epub 2016 Mar 11. PMID: 27168810; PMCID: PMC4840782.

77: Eryılmaz MK, Mutlu H, Yalçın Müsri F, Salim DK, Tazegül G, Coşkun HŞ. Severe periocular bleeding induced by bevacizumab in a patient with recurrent glioblastoma multiforme. *J Oncol Pharm Pract*. 2017 Jul;23(5):392-395. doi: 10.1177/1078155216643858. Epub 2016 Apr 22. PMID: 27105898.

78: Artaç M, Coşkun HŞ, Korkmaz L, Koçer M, Turhal NS, Engin H, Dede İ, Paydaş S, Öksüzoğlu B, Bozcuk H, Demirkazık A. Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study. *Clin Genitourin Cancer*. 2016 Aug;14(4):e347-53. doi: 10.1016/j.clgc.2016.04.021. Epub 2016 May 2. PMID: 27236771.

79: Say F, Coşkun HS, Erdoğan M, Bülbül AM, Gürler D. Causes of open fractures: orthopaedic injuries related to home-made agricultural vehicles in the eastern Black Sea region of Turkey. *Turk J Med Sci*. 2016 Jun 23;46(4):972-6. doi: 10.3906/sag-1411-151. PMID: 27513392.

80: Artaç M, Coşkun HŞ, Dane F, Karabulut B, Korkmaz L, Karaağaç M, Çabuk D, Karabulut S, Faruk Aykan N, Doruk H, Avcı N, Turhal NS. Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study. *J Gastrointest Cancer*. 2016 Sep;47(3):264-72. doi: 10.1007/s12029-016-9823-7. PMID: 27126591.

81: Mutlu H, Salim DK, Gündüz Ş, Eryılmaz MK, Musri FY, Coşkun HŞ. Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard? *J Cancer Res Ther*. 2017 Jul-Sep;13(3):510-513. doi: 10.4103/0973-1482.161933. PMID: 28862218.

82: Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Hegemann M, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Del Muro XG, Rodriguez-Vida A, Cicin I, Harputluoglu H, Widau RC, Liepa AM, Walgren RA, Hamid O, Zimmermann AH, Bell-McGuinn KM, Powles T; RANGE study investigators. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. *Lancet*. 2017 Nov 18;390(10109):2266-2277. doi: 10.1016/S0140-6736(17)32365-6. Epub 2017 Sep 12. PMID: 28916371.

83: Eryılmaz MK, Mutlu H, Tazegül G, Eryılmaz R, Müsri FY, Salim DK, Ünal B, Coşkun HŞ. Multiple pelvic cysts in a patient with familial Mediterranean fever: Benign cystic mesothelioma. *J Cancer Res Ther*. 2017 Oct-Dec;13(6):1047-1049. doi: 10.4103/jcrt.JCRT_125_16. PMID: 29237974.

84: Eryilmaz MK, Mutlu H, Ünal B, Salim DK, Musri FY, Coşkun HŞ. The importance of stromal and intratumoral tumor lymphocyte infiltration for pathologic complete response in patients with locally advanced breast cancer. *J Cancer Res Ther.* 2018 Apr-Jun;14(3):619-624. doi: 10.4103/0973-1482.174550. PMID: 29893329.

85: Korkmaz L, Coşkun HŞ, Dane F, Karabulut B, Karaağaç M, Çabuk D, Karabulut S, Aykan NF, Doruk H, Avcı N, Turhal NS, Artaç M. Kras-mutation influences outcomes for palliative primary tumor resection in advanced colorectal cancer-a Turkish Oncology Group study. *Surg Oncol.* 2018 Sep;27(3):485-489. doi: 10.1016/j.suronc.2018.05.032. Epub 2018 May 30. PMID: 30217306.

86: Moehler M, Ryu MH, Dvorkin M, Lee KW, Coşkun HŞ, Wong R, Chung HC, Poltoratsky A, Tsuji A, Yen CJ, Muntean AS, Le Sourd S, Vaccaro GM, Overton L, Boku N, Wainberg ZA, Patel M, Sharma M, Xiong H, Conti I, Taieb J, Bang YJ. Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design. *Future Oncol.* 2019 Feb;15(6):567-577. doi: 10.2217/fo-2018-0668. Epub 2018 Oct 31. PMID: 30379568.

87: Musri FY, Mutlu H, Eryilmaz MK, Salim DK, Tazegul G, Coşkun HŞ. Hypercalcemia associated with squamous cell carcinoma of renal pelvis: A case and review of the literature. *J Cancer Res Ther.* 2019 Mar;15(Supplement):S170-S172. doi: 10.4103/0973-1482.187236. PMID: 30900642.

88: Arıkan F, Uçar MA, Kondak Y, Tekeli A, Kartöz F, Özcan K, Göksu SS, Coşkun HŞ. Reasons for complementary therapy use by cancer patients, information sources and communication with health professionals. *Complement Ther Med.* 2019 Jun;44:157-161. doi: 10.1016/j.ctim.2019.03.017. Epub 2019 Mar 26. PMID: 31126549.

89: Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, Easton V, Lindegger N, Miles D; PERUSE investigators. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). *Ann Oncol.* 2019 May 1;30(5):766-773. doi: 10.1093/annonc/mdz061. PMID: 30796821.

90: Artaç M, Korkmaz L, Coşkun HŞ, Dane F, Karabulut B, Karaağaç M, Çabuk D, Karabulut S, Aykan NF, Doruk H, Avcı N, Turhal NS. Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients. *J Gastrointest Cancer.* 2019 Jun;50(2):214-220. doi: 10.1007/s12029-017-0047-2. PMID: 29302856.

92: Uçar MA, Arıkan F, Coşkun HŞ, Kondak Y, Tatlı AM, Göksu SS. Fertility in testicular cancer patients: a single-centre study in Turkey. *Int J Clin Oncol.* 2020 Mar;25(3):495-500. doi: 10.1007/s10147-019-01534-7. Epub 2019 Aug 26. Erratum in: *Int J Clin Oncol.* 2019 Dec 3;; PMID: 31452020.

94: Uçar MA, Arıkan F, Coşkun HŞ, Kondak Y, Tatlı AM, Göksu SS. Correction to: Fertility in testicular cancer patients: a single-centre study in Turkey. *Int J Clin Oncol.* 2020 Mar;25(3):501. doi: 10.1007/s10147-019-01572-1. Erratum for: *Int J Clin Oncol.* 2020 Mar;25(3):495-500. PMID: 31797189.

93: Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain SA, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Bedke J,

Gakis G, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Garcia Del Muro X, Rodriguez-Vida A, Cicin I, Harputluoglu H, Tagawa ST, Vaishampayan U, Aragon-Ching JB, Hamid O, Liepa AM, Wijayawardana S, Russo F, Walgren RA, Zimmermann AH, Hozak RR, Bell-McGuinn KM, Powles T; RANGE study investigators. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. *Lancet Oncol.* 2020 Jan;21(1):105-120. doi: 10.1016/S1470-2045(19)30668-0. Epub 2019 Nov 18. PMID: 31753727; PMCID: PMC6946880.

95: Dane F, Ozgurdal K, Yalçın Ş, Benekli M, Aykan NF, Yücel İ, Özkan M, Evrensel T, Sevinç A, Coskun HŞ, Sanli UA, Kara IO, Yumuk PF. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study. *BMJ Open.* 2020 Mar 26;10(3):e027665. doi: 10.1136/bmjopen-2018-027665. PMID: 32220908; PMCID: PMC7170555.

96: Yalcin S, Dane F, Oksuzoglu B, Ozdemir NY, Isikdogan A, Ozkan M, Demirag GG, Coskun HS, Karabulut B, Evrensel T, Ustaoglu MA, Ozdemir F, Turna H, Yavuzsen T, Aykan F, Sevinc A, Akbulut H, Yuce D, Hayran M, Kilickap S. Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study. *BMC Cancer.* 2020 Mar 30;20(1):259. doi: 10.1186/s12885-020-06758-9. PMID: 32228512; PMCID: PMC7106641.

97: Arıkan F, Körükçü Ö, Küçükçakal A, Coşkun HŞ. Determination of Self-Efficacy, Body Image and Sexual Adjustment of Women with Breast Cancer. *Eur J Breast Health.* 2020 Mar 30;16(4):282-289. doi: 10.5152/ejbh.2020.5188. PMID: 33062970; PMCID: PMC7535985.

98: Gonulcu SC, Unal B, Bassorgun IC, Ozcan M, Coskun HS, Elpek GO. Expression of Notch pathway components (Numb, Itch, and Siah-1) in colorectal tumors: A clinicopathological study. *World J Gastroenterol.* 2020 Jul 14;26(26):3814-3833. doi: 10.3748/wjg.v26.i26.3814. PMID: 32774060; PMCID: PMC7383841.

99: Peled N, Gillis R, Kilickap S, Froesch P, Orlov S, Filippova E, Demirci U, Christopoulos P, Cicin I, Basal FB, Yilmaz C, Fedor M, Korkmaz T, Paydas S, Gautschi O, Zirtiloglu A, Eralp Y, Cinkir HY, Sezer A, Erman M, Tural D, Turna H, Mazieres J, Dudnik E, Reguart N, Camidge DR, Ng TL, Şenler FÇ, Beypınar İ, Yazılıtaş D, Demirkazık A, Karaoğlu A, Okutur K, Coşkun HŞ, Şendur MAN, Isikdogan A, Cabuk D, Yumuk PF, Yıldız I, Kaplan MA, Özyılkan Ö, Öztop İ, Olmez OF, Aydın K, Aydın A, Meydan N, Grinberg RD, Roisman LC. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients. *Lung Cancer.* 2020 Oct;148:48-54. doi: 10.1016/j.lungcan.2020.07.022. Epub 2020 Jul 27. PMID: 32799090.

100: Alkan A, Yaşar A, Güç ZG, Gürbüz M, Başoğlu T, Sezgin Göksu S, Buğdaycı Başal F, Türk HM, Özdemir Ö, Yeşil Çinkir H, Güven DC, Kuş T, Türker S, Koral L, Karakaş Y, Ak N, Paydaş S, Karcı E, Demiray AG, Demir A, Alan Ö, Keskin Ö, Nayır E, Tanrıverdi Ö, Yavuzşen T, Yumuk PF, Ateş Ö, Coşkun HŞ, Turhal S, Çay Şenler F. Worse patient-physician relationship is associated with more fear of cancer recurrence (Deimos Study): A study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG). *Eur J Cancer Care (Engl).* 2020 Nov;29(6):e13296. doi: 10.1111/ecc.13296. Epub 2020 Aug 30. PMID: 32864838.

101: Tural D, Ölmez ÖF, Sümbül AT, Artaç M, Özhan N, Akar E, Çakar B, Köstek O, Ekenel M, Erman M, Coşkun HŞ, Selçukbiricik F, Keskin Ö, Türköz FP, Oruç K, Bayram S, Yılmaz U, Bilgetekin İ, Yıldız B, Şendur MAN, Paksoy N, Dirican A, Erdem D, Selam M, Tanrıverdi Ö, Paydaş S, Urakçı Z, Atağ E, Günçan S, Ürün Y, Alkan A, Kaya AO, Özyükseler DT, Taşkaynatan H, Yıldırım M, Sönmez M, Başoğlu T, Gündüz Ş, Kılıçkap S. Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences. *Eur Urol Focus*. 2020 Sep 30:S2405-4569(20)30269-8. doi: 10.1016/j.euf.2020.09.010. Epub ahead of print. PMID: 33008789.

102: Moehler M, Dvorkin M, Boku N, Özgüroğlu M, Ryu MH, Muntean AS, Lonardi S, Nechaeva M, Bragagnoli AC, Coşkun HS, Cubillo Gracian A, Takano T, Wong R, Safran H, Vaccaro GM, Wainberg ZA, Silver MR, Xiong H, Hong J, Taieb J, Bang YJ. Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. *J Clin Oncol*. 2021 Mar 20;39(9):966-977. doi: 10.1200/JCO.20.00892. Epub 2020 Nov 16. PMID: 33197226; PMCID: PMC8078426.

103: Tatli AM, Urakci Z, Tastekin D, Koca D, Goksu SS, Uyeturk U, Kaplan MA, Coskun HS. A retrospective evaluation of geriatric patients with gastric cancer receiving systemic chemotherapy. *J Cancer Res Ther*. 2020 Dec;16(Supplement):S138-S143. doi: 10.4103/jcrt.JCRT_563_18. PMID: 33380668.

104: Eryılmaz MK, Tazegul G, Ünal B, Müsri FY, Güzel HG, Coşkun HŞ. Rapidly developing facial and intertriginous hyperpigmentation with acral erythema after docetaxel infusion. *J Cancer Res Ther*. 2021 Jan-Mar;17(1):293-294. doi: 10.4103/jcrt.JCRT_385_17. PMID: 33723176.

105: NazimTurhal S, Dogan M, Esendagli G, Artac M, Korkmaz L, Coskun HS, Goker E, PerranYumuk F, Bilgetekin I, Kose F, Uncu D, Kavgaci H, Akyol G, Ozet A, Yagci T. The Relationship Between Plexin C1 Overexpression and Survival in Hepatocellular Carcinoma: a Turkish Oncology Group (TOG) Study. *J Gastrointest Cancer*. 2021 Mar 3. doi: 10.1007/s12029-021-00602-4. Epub ahead of print. PMID: 33656690.

106: Canatan D, Sönmez Y, Yılmaz Ö, Çim A, Coşkun HŞ, Sezgin Göksu S, Ucar S, Aktekin MR. MicroRNAs as biomarkers for breast cancer. *Acta Biomed*. 2021 May 12;92(2):e2021028. doi: 10.23750/abm.v92i2.9678. PMID: 33988168; PMCID: PMC8182592.

107: Koçer M, Muallaoğlu S, Çetin B, Coşkun HŞ, Karahan N, Gürdal O. Second Primary Tumors in Patients with Gastrointestinal Stromal Tumors: A Single-Center Experience. *Medicina (Kaunas)*. 2021 May 13;57(5):494. doi: 10.3390/medicina57050494. PMID: 34068309; PMCID: PMC8153290.

108: Tural D, Ölmez ÖF, Sümbül AT, Özhan N, Çakar B, Köstek O, Ekenel M, Erman M, Coşkun HŞ, Selçukbiricik F, Keskin Ö, Türköz FP, Oruç K, Bayram S, Bilgetekin İ, Yıldız B, Şendur MAN, Paksoy N, Dirican A, Erdem D, Selam M, Tanrıverdi Ö, Paydaş S, Urakçı Z, Atağ E, Günçan S, Ürün Y, Alkan A, Kaya AO, Özyükseler DT, Taşkaynatan H, Yıldırım M, Sönmez M, Başoğlu T, Gündüz Ş, Kılıçkap S, Artaç M. Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab. *Int J Clin Oncol*. 2021 Aug;26(8):1506-1513. doi: 10.1007/s10147-021-01936-6. Epub 2021 May 23. PMID: 34023933.

109: Sari M, Ilhan Y, Sezgin Goksu S, Kostek O, Tatli AM, Coskun HS. The Relationship between Nutritional Parameters and Thrombosis Risk in Cancer Patients. *Nutr Cancer*. 2021 Jul 26;1-6. doi: 10.1080/01635581.2021.1952631. Epub ahead of print. PMID: 34309454.

110: Göksu SS, Tatlı AM, Geredeli Ç, Atıcı M, Besen AA, Mertsoylu H, Uysal M, Özdoğan M, Aydın SG, Bilici A, Karaağaç M, Artaç M, Kaplan MA, Ebinç S, Coşkun HŞ. Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck. *Cancer Chemother Pharmacol*. 2021 Jul 26. doi: 10.1007/s00280-021-04328-9. Epub ahead of print. PMID: 34312705.

111: Uysal M, Bozcuk H, Sezgin Göksu S, Murat Tatli A, Arslan D, Gündüz S, Senol Coskun H, Ozdogan M, Savas B. Basal proteinuria as a prognostic factor in patients with metastatic colorectal cancer treated with bevacizumab. *Biomed Pharmacother*. 2014 May;68(4):409-12. doi: 10.1016/j.biopha.2014.03.002. Epub 2014 Mar 18. PMID: 24721326.

112: M. Uysal, M. Ozdogan, A. Kargi, S. Gündüz, S.S. Göksu, A.M. Tatli, D. Arslan, H.Mutlu, H.Ş. Coşkun, H. Bozcuk " Prolonged progression-free survival with maintenance metronomic oral cyclophosphamide and etoposide treatment in macroscopic residual disease or recurrent/advanced stage ovarian cancer" *JBUON* 19(4), 980-984, 2014.

113: Arslan O , **Coşkun HŞ**, Arat M, Çelebi Ç, Özcan M, Gürman G, Üstün C, Akan H, Demirer T, Akan H, İlhan O, Konuk N, Beksaç M, Uysal A, Koç H. Allogeneic peripheral blood stem cell transplantation for standart risk leukemia: 3-year experience of İbni-Sina Hospital. *Bone Marrow Transplantation*, 25 (12): 1229-1232, (2000).

114:. Eser B, Çetin M, Kontaş O, Unal A, Er O, **Coşkun HŞ**, Altınbaş M. Facial nerve paralysis and paraplegia as presenting symptoms of acute leukemia. *J Japan Clin Oncol*; 31 (2): 86-88, (2001).

115: Er O, **Coşkun HŞ**, Altınbas M, Akgün H, Çetin M, Eser B, Ünal A. Rapidly relapsing squamous cell carcinoma of renal pelvis associated with paraneoplastic syndromes of leukocytosis, thrombocytosis and hypercalcemia. *Urologia Internationalis*;67: 175-177, (2001)

116: Soyuer I, Soyuer S, Canöz O, **Coşkun HŞ**, Balkanlı S. Mesothelioma methastas in unusual site: three cases. *Cytapathology*; 15 (1); 2, 58-62. (2004)

117: İcli F, Akbulut H, Uner A, Yalcin B, Baltali E, Altınbas M, **Coşkun HŞ**, Komurcu S, Erkisi M, Demirkazık A, Senler FC, Sencan O, Buyukcelik A, Boruban C, Onur H, Zengin N, Sak SD. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. *Br J Cancer*; Feb 28;92(4):639-44. (2005)

118: Metin Özkan, Bulent Eser, Özlem Er, **H. Şenol Coskun**, Ahmet Öztürk, İsmail Sarı, Özlem Canoz, Mustafa Altınbas. Bone marrow involvement in small cell lung cancer: Prognostic significance and correlation with hematological and biochemical parameters. *Asia-Pacific Journal of Clinical Oncology* 2006; 2: 32-38.

119: Ozlem ER, Metin OZKAN, Mustafa ALTINBAS, **Hasan Senol COSKUN**, Bulent ESER, Fevzi ALTUNTAS, Mustafa CETIN, Ali UNAL. Outpatient 5-fluorouracil+ alfa-interferon+ interleukin-2 chemoimmunotherapy in metastatic renal cell cancer patients (p 145-150) Asia-Pacific Journal of Clinical Oncology 2005; 1:145-150

120: Cure E , Sahin M , Kuducan A, Tunc SE, Baturk A, **Coskun HS**. Rheumatological complaints and findings of cancer patients who were followed in our oncology clinic , Nobel Medicus. 4 (1): 22-27, Jan-Apr 2008.

121: A.N. Kişioğlu, E. Uskun, A.S. Kiliç, E. Uzun, **H.S. Coşkun**, T. Nayir, K. Öngel An epidemiological evaluation on cancer in the province of Burdur, Turkey. Biomedical Research 2008; 19 (3): 168-175

122: Hasan Şenol Coskun, Mustafa Altınbas, Özlem Er, Figen Özturk, Hatice Karaman, Serdar Soyuer, Metin Özkan, Isin Soyuer. Human epidermal growth factor receptor 2 oncoprotein expression in breast cancer patients from central Anatolia, Turkey. Asia-Pacific Journal of Clinical Oncology 2009; **5**: 206-211

123: F. Icli, H. Akbulut, B. Yalcin, F. Ozdemir, A. Isikdogan, M. Hayran, D. Unsal, **S. Coskun**, A. Buyukcelik, D. Yamac . Education, economic status and other risk factors in gastric cancer: "a case-control study of Turkish oncology group. Med Oncol. DOI 10.1007/s12032-009-9406-6, 2011

124: Bozcuk H, Abali H, **Coskun S**; On behalf of the Lung Cancer Committee of Turkish Oncology Group. The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis. World J Surg Oncol. 2012 Aug 9;10(1):161. PubMed PMID: 22877422; PubMed Central PMCID: PMC3463432.

125: Abali H, Ata A, Ozdogan M, Turhal S, Cabuk D, Seyrek E, Senol Coskun H, Arik Z, Erman M, Celik I. Frequency of comorbid illnesses in cancer patients in Turkey. J BUON. 2011 Jul-Sep;16(3):557-60.

126: H. Bozcuka, K. Ozcan, C. Erdogan, H. Mutlu, M. Demir, S. Coskun. A comparative study of art therapy in cancer patients receiving chemotherapy and improvement in quality of life by watercolor painting. Complementary Therapies in Medicine. Volume 30, February 2017, Pages 67-72

127: Deniz Tural1 · Fatih Selçukbiricik2 · Ömer Fatih Ölmez3 · Ahmet Taner Sümbül4 · Mustafa Erman5 · Hasan Şenol Coşkun6 · Mehmet Artaç7 · Saadettin Kılıçkap8 Response to first-line chemotherapy regimen is associated with efficacy of immune checkpoint blockade therapies in patients with metastatic urothelial carcinoma. International Journal of Clinical Oncology <https://doi.org/10.1007/s10147-021-02072-x>

128: Hakan Bozcuk1 · Hasan Şenol Coşkun2 · Yusuf İlhan2 · Sema Sezgin Göksu2 · Mustafa Yıldız3 · Selami Bayram3 · Tahir Yerlikaya3 · Murat Koçer3 · Mehmet Artaç4 · Muzafer Uğraklı4 · Ayberk Ouisupov1 · Alev Aydeniz1 · Dilhun Şahin1 · Gözde Yalçın1 · Meliha Saatçi1 · Hasan Mutlu1 · Mustafa Yıldırım5 Prospective external validation of an updated algorithm to quantify risk of febrile neutropenia in cancer patients after a cycle of chemotherapy Supportive Care in Cancer <https://doi.org/10.1007/s00520-021-06681-0>

129: Sema Sezgin Göksu1 · Ali Murat Tatlı1 · Çağlayan Geredeli2 · Mustafa Atıcı2 · Ali Ayberk Besen3 · Hüseyin Mertsoylu3 · Mükremin Uysal4 · Mustafa Özdoğan4 ·

Sabin Göktaş Aydın⁵ · Ahmet Bilici⁵ · Mustafa Karağaç⁶ · Mehmet Artaç⁶ · Muhammet Ali Kaplan⁷ · Senar Ebinç⁷ · Hasan Şenol Coşkun¹ Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck Cancer Chemotherapy and Pharmacology (2021) 88:805–812 <https://doi.org/10.1007/s00280-021-04328-9>

130: KARAKURT ERYILMAZ MELEK,MUTLU HASAN,ÜNAL BETÜL,KIVRAK SALIM DERYA,YALÇIN MÜSRI FATMA,COSKUN HASAN SENOL (2018). The importance of stromal and intratumoral tumor lymphocyte infiltration for pathologic complete response in patients with locally advanced breast cancer. Journal of Cancer Research and Therapeutics, 14(3), 619-624., Doi: 10.4103/0973-1482.174550 (Yayın No: 5826974)

B. Uluslararası bilimsel toplantılarda sunulan ve bildiri kitabında (Proceedings) basılan bildiriler :

B1. Arman D, **Coşkun HŞ**, Özcan M, Koç H, Akan H, Uysal A, Beksaç M, İlhan O, Konuk N. Imipenem-amikacin as initial or secondary treatment in febrile neutropenic patients. First European Congress of Chemotherapy, Glasgow, Scotland 14-17 May 1996.

B2. **Coşkun HŞ**, İlhan O, Ayaz S, Davla K, Üstün C, Arat M, Beksaç M. Serum transforming growth factor beta 1 levels in multiple myeloma. American Society of Hematology. Fortieth Annual Meeting December 4-8, 1998. Miami Beach, Fl. Blood , 92 (10). Supplement 1, November 15, 1998

B3. İlhan O, Demirer T, Arat M, Davla K, **Coşkun HŞ**, Beksaç M, Akan H, Özcan M, Arslan O, Gürman G, Koç H. The influence of CD41+ and CD42+ peripheral blood stem cells on platelet engraftment after Allo PBSCT. 25th Annual Meeting European Group for Blood and Marrow Transplantation. Hamburg March 21-25- 1999. Bone Marrow Transplantation. 23 Supplement 1. March 1999.

B4. Arat M, Demirer T, Üstün C, Çelebi Ç, Tüzün A, **Coşkun HŞ**, Ayyıldız E, İlhan O, Gürman G, Özcan M, Koç H. A phase I dose escalation study of high dose thiotepa, melphalan and carboplatin (TMC) followed by autologous peripheral blood stem cell transplantation in patients with high risk breast cancer and hematologic malignancies. American Society of Clinical Oncology. Thirty-fifth annual meeting May 15-18, 1999 Atlanta, GA, USA

B5. İlhan O, Demirer T, Arat M, Arslan Ö, Dalva K, **Coşkun HŞ**, Beksaç M, Akan H, Özcan M, Gürman G, Koç H. Platelet engraftment after allo PBSCT: the role of CD41+ and CD42+ stem cells. Fourth Congress of the European Association. Barcelona, Spain, June 9-12, 1999. Haematologica 84 (EHA-4 Abstract Book), June 1999, p: 66

B6. Arslan Ö, **Coşkun HŞ**, Üstün C, Arat M, Çelebi H, Özcan M, Gürman G, Akan H, İlhan O, Konuk N, Demirer T, Beksaç M, Uysal A, Koç H. Experience of ibni Sina hospital in allogeneic peripheral stem cell transplantation for standart risk leukemia patients. Fourth Congress of the European Association. Barcelona, Spain, June 9-12, 1999. Haematologica 84 (EHA-4 Abstract Book), June 1999, p: 66

B7. Arslan Ö, Akan H, Arat M, Üstün C, **Coşkun HŞ**, Özcan M, Gürman G, İlhan O, Belsaç M, Konuk N, Uysal A, Koç H. Soluble adhesion molecules in allogeneic peripheral stem cell donors primed with rhG-CSF. Fourth Congress of the European Association. Barcelona, Spain, June 9-12, 1999. Haematologica 84 (EHA-4 Abstract Book), June 1999, p: 200

- B8.** Üstün C, Belsaç M, Dalva K, Konuk N, Koç H, İlhan O, Özcan M, Gürman G, Akan H, Arat M, Çelebi H, **Coşkun HŞ**, Uysal A. The results off all-trans retinoic acid treatment on bcl2 expression and rhodamine retention in de novo AML. Fourth Congress of the European Association. Barcelona, Spain, June 9-12, 1999. Haematologica 84 (EHA-4 Abstract Book), June 1999, p: 231
- B9.** Üstün C, İdilman R, Bozkaya H, Çelebi H, Arat M, **Coşkun HŞ**, Bozdayı M, İlhan O. Hepatiits G virus in the sera of patients with aplastic anaemia. Fourth Congress of the European Association. Barcelona, Spain, June 9-12, 1999. Haematologica 84 (EHA-4 Abstract Book), June 1999, p: 284
- B10.** Ünal A, Çetin M, Eser B, **Coşkun HŞ HŞ**. Low dose idarubicine, vincristine, prednisone, and G-CSF plus ATRA for the treatment of poor risk myelodysplastic syndrome (MDS). American Society of Hematology. Forty-first Annual Meeting December 3-7, 1999. New Orleans LA. USA. Blood 1999; 94 (10 suppl 1):282b.
- B11.** Ünal A, Çetin M, Patiroğlu T, Eser B, **Coşkun HŞ**, Altınbaş M, İlhan O, Uysal A. Non frozen autologous peripheral blood stem cell transplantation in relapsing and resistant lymphoma. 26th Annual Meeting European Group for Blood and Marrow Transplantation. Innsbruck, Austria. March 5-8, 2000. Bone Marrow Transplantation 2000; 25 (Suppl 1): S175.
- B12.** **Coşkun HŞ**, Eser B, Çetin M, Ünal A, Altınbaş M, Er O, Karahacıoğlu E, Kaplan B. Hodgkin Disease: results of single center in Central Anatolia of Turkey. American Society of Clinical Oncology. Thirty-sixth annual meeting May 20-23, 2000-New Orleans, LA, USA
- B13.** Er O, **Coşkun HŞ**, Altınbaş M, Eser B, Keklik M, Cetin M, Karahacıoğlu E, Ünal A. Efficacy of vinorelbine and doxorubicin combination chemotherapy in metastatic breast cancer. European School Of Oncology. 2nd Milan Breast Cancer Conference. June 14-16, Milan İtaly
- B14.** Unal A, Cetin M, Eser B, Gucer S, Tayyar M, Er O, **Coşkun HŞ**. Activated protein C resistance in Turkish Women With pre-eclampsia. 5th Annual Meeting of the European Haematology Association, Birmingham 25-28 June 2000, UK p:500
- B15.** **Coşkun HŞ**, Er O, Altınbas M, Tanrıverdi F, Eser B, Ünal A, Çetin M. Adjuvant treatment of locally advanced gastric cancer. A retrospective analysis. 25th European Society for Medical Oncology Congress, 13-17 October 2000, Hamburg Germany. Annals of Oncology 2000, 11(Suppl 4): p117
- B16.** Ünal A, Eser B, Çetin M, Altınbas M, Karahacıoğlu E, Kontaş O, Kaplan K, Er O, **Coşkun HŞ**. Clinico-pathologic caharacteristics of non-Hodgkins lymphoma patients at single center in Central Anatolia. 25th European Society for Medikal Oncology Congress, 13-17 October 2000, Hamburg Germany. Annals of Oncology 2000, 11(Suppl 4): 102
- B17.** Altınbas M, Ozkan M, **Coşkun HŞ**, Er O, Eser B, Ünal A, Çetin M. Efficiency of cyclophosphamide, epirubicine, vincristine (CEV) ± low molecular weight heparin (LMWH) in small cell lung cancer (SCLC): Preliminary results. 25th European Society for Medical Oncology Congress, 13-17 October 2000, Hamburg Germany. Annals of Oncology 2000, 11(Suppl 4): 71
- B18.** Cetin M, Ünal A, Eser B, Patiroğlu T, Arslan O , Er O, **Coşkun HŞ**. Effects of DMSO on P selectin expression during storage of platelet concentrates. American Society of

Hematology. Forty-second Annual Meeting December 1-5, 2000. San Francisco, California, USA. Blood , 96 (11)., November 16, 2000.

B19. Altınbaş M, **Coşkun HŞ**, Er O, Ozkan M, Eser B, Unal A, Cetin M. Prospective Randomized Study Of Epirubicine Cyclophosphamide And Vincristine Combination Chemotherapy (CEV) ± Low Molecular Weight Heparin (LMWH) In Small Cell Lung Cancer (SCLC). Proceedings of ASCO VOL 20 2001;321a.

B20. Er O, **Coşkun HŞ**, Altınbaş M, Eser B, Çetin M, Ünal A. Epidemiological Characteristics and Results Of Adjuvant Treatment of Colorectal Cancer Patients From Erciyes University Oncology Hospital in Turkey. Proceedings of ASCO vol 20 2001;114b

B21. Ünlühizarcı K, Çolak R, Bayram F, Sözüer E, Er Ö, **Coşkun HŞ**; Keleştimur F. Adrenocortical carcinoma presenting with hirsutism: Report of three patients. International Conference on Consequences in adult age of Endocrine Diseases in childhood. Thessaloniki, Greece May 10-12, 2001

B22. Er O, **Coşkun HŞ**, Altınbaş M, Gülmez İ, Eser B, Çetin M, Ünal A. Cisplatin and etoposide versus cisplatin and vinorelbine: a retrospective comparison in patients with advanced nonsmall cell lung cancer (NSCLC). International Symposium Lung Cancer and Bronchoscopy 29 Aug-1Sep 2001, İstanbul, Turkey.

B23. Altınbaş M, Er O, **Coşkun HŞ**, Soyuer S, Eser B, Çetin M, Ünal A, Karahacıoğlu E. Palliative chemotherapy in inoperable or metastatic pancreatic carcinomas. 4th International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies Sep 6-8,2001; 84, Germany.

B24. Altınbaş M, Er O, **Coşkun HŞ**, Ekici E, Gülmez İ, Özemesi M. İfosfamide, mesna and interferon alfa combination therapy in malignant mesothelioma: Results of a single center in central Anatolia, Turkey. European J Cancer 2001: vol 37 sup 6; 46-47

B25. Ünal A, Çetin M, Eser B, Patiroğlu T, **Coşkun HŞ**, Er O, Kaplan B, Altınbaş M. Autologous Peripheral Blood Stem Cell Transplantation In Patients with Resistant and/or Relapsing Lymphoma: Single center experience. Forty-third Annual Meeting December 7-11, 2001. Orlando Florida USA. Blood 2001; 98(11): 400b.

B26. **Coşkun HŞ**, Er O, Altınbaş M, Eser B, Unal A, Çetin M. Efficacy of cisplatin etoposide combination in anthracycline refractory metastatic breast cancer. The Breast Journal 2001;7(5): 43.

B27. **Coşkun HŞ**, Er O, Altınbaş M, Çoban Ö, Çetin M, Eser B. Docetaxel and doxorubicin combination in salvage therapy of metastatic breast cancer. The Breast Journal 2001;7(5): 43-44.

B28. Er O, **Coşkun HŞ**, Altınbaş M, Eser B, Unal A, Çetin M. Paclitaxel and epirubicin combination therapy in metastatic breast cancer patients. The Breast Journal 2001;7(5): 69.

B29. Er O, **Coşkun HŞ**, Soyuer I, Altınbaş M. Late onset of local recurrence and distant metastases from breast cancer. The Breast Journal 2001;7(5): 71.

B30. Altınbaş M, **Coşkun HŞ**, Er O, Ünal A. Docetaxel and doxorubicin combination in salvage therapy of metastatic breast cancer. 25th German Cancer Congress. 10-14 March 2002, Berlin Germany. Cancer Research Clinical Oncology 2002; 128 (Supply 1): S52.

B31. Arsan O, Arat M, Soydan E, **Coşkun HŞ**, Topcuoglu P, Özcan M, Gürman G, Demirer T, İlhan O, Koc H, Beksac M, Konuk N, Uysal A, Akan A. Does doner recipient ABO-incompatibility have any effect on the course and outcome of allogeneic hematopoietic cell transplantation? 28th Meeting of Physicians. European Group for Blood and Marrow Transplantation. March 24-27 2002, Montreux Switzerland. Bone Marrow Transplantation 2002; 29 (Suppl 2): S214-S215.

B32. Er O, **Coşkun HŞ**, Solak Y, Altınbas M. Irinotecan Plus Cisplatin Combination Against Metastatic Gastric Adenocarcinoma: Preliminary Results of Phase II Study. American Society of Clinical Oncology. Thirty-Eighth annual meeting May 18-21, 2002 Orlanda FL, USA Prog Proceeding of ASCO Vol: 21, 2002 Abstract: 2310.

B33. Ünal A, Eser B, Canöz Ö, Kaplan B, Sarı HI, **Coşkun HŞ**, Er O, Altınbaş M, Çetin M. Clinicopathologic characteristics and prognostics factors of primary gastrointestinal non-Hodgkin's lymphoma. 7th Meeting of the European Hematology 6-9 June 2002, Italy. The Hematology Journal 2002; 3(Supply 1): 267-268.

B34. Eser B, Ünal A, Başkol M, Çetin M, Çakmak E, **Coşkun HŞ**, Er O. Elevated transaminase levels in patients with vitamin B12 Deficiency. 7th Meeting of the European Hematology 6-9 June 2002, Italy. The Hematology Journal 2002; 3(Supply 1): 384.

B35. **Coşkun HŞ**, Altınbas M, Er O, Öztürk F, Karaman H, Soyuer S, Ozkan M, Soyuer I. HER2 expression in Turkish breast cancer patients from a single center. 27th ESMO Congress 18-22 October, 2002 Nice-France. Annals of Oncology 2002, 13(Supplement 5): 41.

B36. Er O, **Coşkun HŞ**, Altınbas M, Ozkan M, Eser B, Çetin M, Altuntaş A, Ünal A. Meropenem+/- granulocyte colony stimulating factor in treatment of febrile neutropenic patients wit cancer: Prospective randomized study. 27th ESMO Congress 18-22 October, 2002 Nice-France. Annals of Oncology 2002, 13(Supplement 5): 176.

B37. Altınbas M, Er O, **Coşkun HŞ**, Ozkan M, Eser B, Çetin M, Altuntaş F, Ünal A. Gemcitabine and sisplatin in the treatment of advanced or metastatic pancreatic cancer. 27th ESMO Congress 18-22 October, 2002 Nice-France. Annals of Oncology 2002, 13(Supplement 5): 194.

B38. Er O, Ozkul Y, Altınbas M, Gursoy S, **Coşkun HŞ**, Ozkan M, Tekin S, Akalin H. K-ras codon 12 mutations in colorectal cancer patients. American Society of Clinical Oncology. Thirty-Ninth annual meeting May 31- June 3, 2003 Chicago, Illinois, USA Prog Proceeding of ASCO Vol: 22, 2003 Abstract: 1238.

B39. Altınbas M, Ozkan M, Er O, Everest H, **Coşkun HŞ**, Menku A, Cihan Y, Kaplan B. Adjuvant radiotherapy and fotemustine in treatment of anaplastic astrocytoma and glioblastoma multiforme patients. American Society of Clinical Oncology. Thirty-Ninth annual meeting May 31- June 3, 2003 Chicago, Illinois, USA Prog Proceeding of ASCO Vol: 22, 2003 Abstract: 459.

B40. Eser B, Altuntaş F, Kaplan B, Canöz O, Özkan M, Er O, **Coşkun HŞ**, Gündoğan K, Cetin M, Ünal A. Results of first line treatment in Hodgkin's Disease: Single center experience. 8th Annual Congress of the European Hematology Association. 12-15 June 2003 France. The Hematology Journal 2003; 4: Supplement 2: Abstract 0355.

B41. **Coşkun HŞ**, Er O, Ozkan M, Eser B, Altınbas M. Adjuvant sequential docetaxel and cyclophosphamide-doxorubicin combination in operable breast cancer patients. 40TH

Annual meeting ASCO. 2004 Annual Meeting Proceeding, Journal of Clinical Oncology 2004; 22(14S):82S (A:822).

B42. Er O, Ozkan M, Altınbaş M, **Coşkun HŞ**, Eser B, Altuntaş A, Cetin M, Unal A. Fluorouracil+interferon alfa+interleukin-2 chemoimmunotherapy in metastatic renal cell cancer patients. 40TH Annual meeting ASCO. 2004 Annual Meeting Proceeding, Journal of Clinical Oncology 2004; 22(14S):427S (A: 4682).

B43. Coşkun HŞ, Yilmaz O, Alanoğlu G, Şahin M, Er Ö, Ergürhan İlhan İ. Chemotherapy associated anemia in solid tumor patientst from Anatolia. ASCO 41st Annual Meeting proceedings. J Clinincal Oncology 2005; 23: (16S): 729s, P: 8257.

B44. F. Coskun Ari, G. Bosgelmez, **H.S. Coskun**, M. Polat, N. Kisioglu, I. Ergurhan Ilhan. Deletion polymorphism of the GSTM1 gene in lung cancer patients from the Lake District in Turkey. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 20089

B45. H. Coskun, N. Karakus, H. Vural, O. Akturk, G. Alanoglu. Effects of low molecular weight heparin on angiogenic factors in advanced cancer patients Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 21158.

B46.Güçhan Alanoğlu, Bülent Kara, Sema Sezgin Goksu, Nilgun KApucuoğlu, Hasan Şenol Coşkun. Lymphoma experince of lakes distrint from Süleyman Demirel Universty school of Medicine. 1 st International Lymphoma-Leukemia-Myeloma (LLM) Congres. May 20-27, 2007 İsyambul.

B47. Savas B, Kargi A, Ekinci D, Artac M, Ozdogan M, Bozcuk H, Coskun HS. Metronomic cyclophosphamide-based chemotherapies, bevacizumab-based chemoimmunotherapies and serum VEGF levels in metastatic cancer patients. The 8th Princes Margaret Hospital Conference Developments in Cancer Management: October 16-18 2008 Totonto.

B48. H. Mutlu, H. Bozcuk, M. Ozdogan, M. Artac, H. S. Coskun, A. Kargi, M. Uysal, B. Savas; Impressive survival data with semimetronomic oral chemotherapy with old agents in heavily treated metastatic breast cancer patients. J Clin Oncol 27:15s, 2009 (suppl; abstr 1082

B49. H.S. Bozcuk, M. Ozdogan, H.S. Coskun, H. Mutlu, A. Kargi, M. Uysal, B. Savas; High-dose chemotherapy and stem cell support in the management of metastatic germ cell cancer: A quantitative review. Clin Oncol 2009, 27; (suppl; abstr e16094)

B50. M. Ozdogan, H. Bozcuk, O. Er, H. Abali, H.S. Coskun, N. Zengin, M. Artac, B. Savas. The predictors of information needs and different views of patients and relatives on disclosure and treatment participation: A multicentric survey study. J Clin Oncol 27, 2009 (suppl; abstr e20526)

B51. A. Kargi, M. Ozdogan, H. Bozcuk, E. Pestereli, M. Artac, H. S. Coskun, H. Mutlu, M. Uysal, S. Karaveli, B. Savas; COX-2 expression and clinical outcome in early-stage breast cancer patients treated with adjuvant chemotherapy: A prospective study. J Clin Oncol 27, 2009 (suppl; abstr e22165).

B52. H. Bozcuk, M. Yildiz, M. Ozdogan, H.S. Coskun, A. Kargi, H. Mutlu, M. Uysal, B. Savas. Determinants of health service satisfaction among cancer patients and their care givers in oncology services: a survey study from two teaching hospitals in Turkey Joint ECCO 15-34Th ESMO Multidisiplinary Congres, Berlin 20-24 September 2009. European Journal of Cancer Supplements, Vol 7 No 2, September 2009, Page 212

B53. M. Ozdogan, H. Bozcuk, K. Ozcan, A. Tekeli, H.S. Coskun, A. Kara, H. Mutlu, A. Kargi, M. Uysal, B. Savas. The cancer education nursing units impact on informational needs of cancer patients - the first Turkish report. Joint ECCO 15-34Th ESMO Multidisciplinary Congress, Berlin 20-24 September 2009. European Journal of Cancer Supplements, Vol 7 No 2, September 2009, Page 250.

B54. H. Bozcuk, H. Mutlu, M. Artac, M. Ozdogan, H.S. Coskun, A. Kargi, M. Uysal, B. Savas. An encouraging chemotherapy regimen in progressive small cell lung cancer - Irinotecan and Ifosfamide: an experience from single center. Joint ECCO 15-34Th ESMO Multidisciplinary Congress, Berlin 20-24 September 2009. European Journal of Cancer Supplements, Vol 7 No 2, September 2009, Page 544.

B55. M. Ozdogan, A. Kargi, M. Artac, H. Bozcuk, M.C. Boruban, H.S. Coskun, H. Mutlu, O.O. Eren, M. Uysal, B. Savas. Maintenance semi-metronomic oral cyclophosphamide and oral etoposide regimen in extensive stage small cell lung cancer (SCLC) patients after responding first line treatment. Joint ECCO 15-34Th ESMO Multidisciplinary Congress, Berlin 20-24 September 2009. European Journal of Cancer Supplements, Vol 7 No 2, September 2009, Page 544.

B56. H. Coskun, D. Coskun, S. Durak, S. Aydin, M. Yildiz. Medical oncologist in Turkey should be aware of national cancer control and screening programme. The 5th APOCP conference, april 3-7, 2010. İstanbul (P-122).

B57. F Özdemir, A Demirel, K Ersoy, HS Coskun, E Kurt, F Aydın. Is advanced parental age a risk factor for colorectal cancer?. Turkish Oncology Group Study. 35Th European Society Medical Oncology (ESMO) Congress, October 08-12, 2010 Milan İtaly. Annals of Oncology 21 (Suppl): 665

B58. E Yaman D Yamaç, S Turhal, B Karaca, HS Coskun, S Komurcu, T Yavuzsen, F Dane, M Nalca, M Akmansu. The impression we give to patients when breaking bad news: A multicenter study in a Turkish Cancer Population. 35Th European Society Medical Oncology (ESMO) Congress, October 08-12, 2010 Milan İtaly. Annals of Oncology 21 (Suppl): 1202P

B59. H. Akbulut, M. K. Altundag, P. Saip, **H. Coskun**, C. Camci, M. Ozkan, S. Paydas, N. Zengin, G. Alco, M. Aliustaoglu, G. Basaran, D. Yamac, I. Yucel, E. Goker, E. Yaman, A. Isikdogan, Y. Y. Ozisik, E. Topuz, M. Ozdogan, F. Icli, BREASTTURK. The changing pattern of risk factors and disease characteristics of breast cancer in Turkey: A cross-sectional study of a Turkish oncology group (BREASTTURK). 2011 ASCO Annual Meeting. J Clin Oncol 29: 2011 (suppl; abstr e12007).

B60. D. Arslan, H. Bozcuk, S. Gunduz, A.M. Tatli, M. Uysal, S. Goksu, D. Tural, **H.S. Coskun**, B. Savas To assess the effect of regular exercise, involvement with art (origami) and group therapy on quality of life, anxiety, depression, patient satisfaction and hope levels in patients with remission who had a variety of cancer diagnoses "quality of life support program (QoLSP)" was developed ECCO 2013

B61. YTTRIUM-90 (γ -90) radioembolization in patients with unresectable liver metastases: Determining the factors that lead to treatment efficacy. S. Gunduz, O. Ozgur, H. Bozcuk, **H.S. Coskun**, M. Ozdogan, M. Erkilic, T. Sindel, A. Yildiz, S. Yilmaz, B. Savas. ECCO 2013

B62. Seyda Gunduz, **Hasan Senol Coskun**, Sema Sezgin Goksu, Deniz Arslan, Ali Murat Tatli, Mukremin Uysal, Burhan Savas, Mustafa Ozdogan. An PET CT predict response in

locally advanced rectal cancer patients treated with induction FOLFOX? 2013 ASCO Annual Meeting, e14696 J Clin Oncol 31, 2013 (suppl; abstr e14696)

B63. Ali Murat Tatli, **Hasan Senol Coskun**, Mukremin Uysal, Sema Sezgin Goksu, Deniz Arslan, Seyda Gunduz, Mustafa Ozdogan, Hakan Sat Bozcuk, Burhan Savas; Capecitabine plus bevacizumab (Cape-Bev) as a maintenance treatment after induction treatment with FOLFIRI plus bevacizumab (FOLFIRI-Bev) in metastatic colorectal cancer (mCRC). 2013 ASCO Annual Meeting, e14683. J Clin Oncol 31, 2013 (suppl; abstr e14683)

B64. Deniz Arslan, Hakan Sat Bozcuk, Ali Murat Tatli, Seyda Gunduz, Mukremin Uysal, Sema Sezgin Goksu, Lokman Koral, **Hasan Senol Coskun**, Burhan Savas; Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system. 2013 ASCO Annual Meeting, e18517. J Clin Oncol 31, 2013 (suppl; abstr e18517)

Abstract: 1529P

Citation: Annals of Oncology, Volume 25, Supplement 4, 2014

EFFECT OF MASSAGE THERAPY ON PERIPHERAL NEUROPATHY AND LIFE QUALITY OF COLORECTAL CANCER WITH PATIENT RECEIVING CHEMOTHERAPY

H.S. Coskun¹, F. Arikan¹, F. Gökdogan²

1 Medical Oncology, Akdeniz University, Antalya, TURKEY

2 Internal Medicine Nursing, Nurse Faculty at Retirement, Bolu, TURKEY

Abstract: 1525P

Citation: Annals of Oncology, Volume 25, Supplement 4, 2014

OPIOID ENDOCRINOPATHY: A CLINICAL PROBLEM IN PATIENTS WITH CANCER PAIN

F. Avci¹, A. Merdin¹, S. Gunduz², H. Bozcuk³, H.S. Coskun³

1 Internal Medicine, Akdeniz University Faculty of Medicine, Antalya, TURKEY

2 Medical Oncology, Antalya Education and Research Hospital, Antalya, TURKEY

3 Medical Oncology, Akdeniz University Faculty of Medicine, Antalya, TURKEY

BIOMARKERS

Poster

Abstract: 241P

Citation: Annals of Oncology, Volume 25, Supplement 4, 2014

THE CORRELATES OF DOSE REDUCTION IN CHEMOTHERAPY FOR PATIENTS WITH COMMON CANCERS. A PROSPECTIVE STUDY

H. Bozcuk¹, M. Yildiz², S. Uçar¹, H. Mutlu¹, H. S. Coskun¹

1 Dept. of Internal Medicine, Akdeniz University Medical Oncology, Antalya, TURKEY

2 Medical Oncology, Antalya Education and Research Hospital Tibbi Onkoloji Klinigi, Antalya, TURKEY

Expression of notch pathway components (Numb, Itch and Siah-1) in colorectal tumours
By: [Gonulcu, SC](#) (Gonulcu, S. Cil)^[1]; [Unal, B](#) (Unal, B.)^[1]; [Ozcan, M](#) (Ozcan, M.)^[1]; [Toru, S](#) (Toru, S.)^[1]; [Bassorgun, CI](#) (Bassorgun, C. I.)^[1]; [Coskun, HS](#) (Coskun, H. S.)^[1]; [Gunduz, S](#) (Gunduz, S.)^[1]; [Elpek, GO](#) (Elpek, G. O.)^[1]

VIRCHOWS ARCHIV

Volume: 465

Pages: S237-S237

Supplement: 1

Meeting Abstract: PS-10-086

Published: AUG 2014

[View Journal Information](#)

Epithelioid hemangioendothelioma presenting with endobronchial lesion: case report

By: [Ozbudak, IH](#) (Ozbudak, I. H.)^[1]; [Toru, HS](#) (Toru, H. S.)^[1]; [Ozbudak, O](#) (Ozbudak, O.)^[1]; [Coskun, HS](#) (Coskun, H. S.)^[1]

VIRCHOWS ARCHIV

Volume: 465

Pages: S373-S373

Supplement: 1

Meeting Abstract: PS-25-053

Published: AUG 2014

[View Journal Information](#)

Author Information

B2. M.Uysal, M.Ozdogan, S.Testemel, A.Mutlu, S.S. Goksu, A.M.Tatli, D.Arslan, S.Gunduz, H.S.Coskun, H.Bozcuk, B.Savas, "Evaluation of The Patients Received Cabazitaxel For Metastatic Prostate Cancer", 2nd Congress of The Mediterranean Multidisciplinary Oncology Forum, 116 Pp.,İstanbul, Türkiye, November 2011. Fotokopi AMT iste

B3. M.Uysal, M.Ozdogan, A.Mutlu, S.Testemel, S.S.Goksu, A.M.Tatli, D.Arslan, S.Gunduz, H.S.Coskun, H.Bozcuk, B.Savas, "Metastatic Malignant Melanoma-Ipilimumab: Treatment Efficacy And Side Effects", 2nd Congress of The Mediterranean Multidisciplinary Oncology Forum, 117 Pp.,İstanbul, Turkey, November 2011. Fotokopi AMT iste

B4. M.Ozdogan, M.Uysal, S.S.Goksu, A.M. Tatli, D. Arslan, S.G. Gunduz, H.S. Coskun, H.Bozcuk, B.Savas, "Prolonged Progression-Free Survival With Oral Cyclophosphamide And Oral Etoposide At Patients With Ovarian Cancer ", 2nd Congress of The Mediterranean Multidisciplinary Oncology Forum, 144 Pp., İstanbul, Türkiye, November 2011. Fotokopi AMT iste

B1. M.Uysal, H.Bozcuk, S.S.Goksu, **A.M.Tatli**, D.Arslan, S.G.Gunduz, H.S.Coskun, M.Ozdogan, B.Savas, "Proteinuria As A Predictive Factor İn Metastatic Colorectal Cancer Patients Treated With Bevacizumab", 2012 ASCO Annual Meeting, 14070 Pp.,Chicago, USA, June 2012.

B2. D.Arslan, H.Bozcuk, S.G.Gündüz, **A.M.Tatlı**, M.Uysal, S.S.Goksu, D.Tural, H.S.Coşkun, B.Savaş, "To Assess The Effect Of Regular Excercise, Involvement With Art (Origami) And Group Therapy On Quality Of Life, Anxiety, Depression, Patient Satisfaction And Hope Levels In Patients With Remission Who Had A Variety Of Cancer Diagnoses "Quality Of Life Support Program (Qolsp)" Was Developed", The European Cancer Congress 2013, 134 Pp.,Amsterdam, Holland, October 2013.

B3. E. Avsar, E. Coban, S.S. Goksu, A.M. Tatlı, H.S.Coskun. Evaluation Vitamin D Levels of Newly Diagnosed Cancer Patients. 2. İnternatıonal Congress on Oncological Sciences.20-23 September 2018 ANTALYA.

C. Yazılan uluslararası kitaplar veya kitaplarda bölümler :

D. Ulusal hakemli dergilerde yayımlanan makaleler:

D1. Coşkun HŞ, Arslan O , Üstün C, Koç H, Akan H. Standart ve lipozomal amfoterisin B'nin nötropenik hastalarda etkinliğinin değerlendirilmesi. Flora.1998, 3 (2): 85-90

D2. Coşkun HŞ, Sarı RA, Şahin M, Turgay M, Kınıklı G. Palmoplanter püstülotik artro-osteitis. Türkiye Tıp Dergisi. 1998, 5 (5): 318-321.

D3. Coşkun HŞ, Sarı RA, Şahin M, Duman M. Akut romatizmam ateşin oluşum mekanizmaları. Kinik Bilimler & Doktor 1999; 5(2): 188-192.

D4. Coşkun HŞ, Samur M, Dinçol D. Non-Hodgkin lenfomalı bir hastada toxoplasma gondii enfeksiyonu. Flora 1999; 4(1): 68-71

D5. Çetin M, Eser B, Ünal A, Er O, Kula M, Öztürk Ö, **Coşkun HŞ,** Altınbas M. ST segment yükselmesi ile seyreden diffüz malign plevral mezotelyomanın perikard invazyonu. Erciyes Tıp Dergisi 1999; 21(4): 229-234,

D6. Arman D, **Coşkun HŞ,** Gürman G, Özcan M, Koç H, Akan H, Uysal A, Beksaç M, İlhan O, Konuk N. Imipenem-amikacin as initial or secondary treatment in febrile neutropenic patients. İnfeksiyon Dergisi 1999; 13 (3): 403-406.

D7. Eser B, Çetin M, Ünal A, **Coşkun HŞ,** Kayabaş Ü, Altınbas M. Kanserli Hastalarda Bakteremi ve fungemi ile birlikteliği olan faktörler. Flora 2000; 5(1): 49-55

D8. Çelebi Ç, Üstün C, Arat M, Akan H, Tunçman G, Özçelik T, **Coşkun HŞ,** Koç H. An extra benefit allogeneic peripheral blood stem cell transplantation in a patient with lymphblastic lymphoma: Cure of thalassemia minor. Turk J Haematol 2000; 17 (2): 73-76

D9. Coşkun HŞ, Er O, Kontaş O, Altınbas M, Karahacıoğlu E, Eser B, Çetin M, Arar M, Ünal A. Soliter İntrakranial Plazmasitom. Türkiye Tıp Dergisi 2000; 7 (4): 195-199.

D10. Er Ö, Altınbaş M, **Coşkun HŞ,** Çetin M, Eser B, Ünal A. Fluourasil bazlı rejimlere dirençli metastatik kolorektal kanserli hastalarda irinotekan kullanımı. Kanser Gündemi 2000, 5(3): 59-60

D11. Coşkun HŞ, Er O, Arar M, Altınbas M, Serin S, Karahacıoğlu E. Uterin serviksın küçük hücreli kanseri. Jinekolojik Onkoloji Dergisi 2000; 3(4): 142-144.

D12. Ünal A, Çetin M, Eser B, Patiroğlu T, Altınbas M, Karahacıoğlu E, Er O, **Coşkun HŞ,** Kaplan B. Allogeneic peripheral blood stem cell transplantation in a patient with AML first case of Erciyes University and review of the literature. Erciyes Tıp Dergisi 2000; 22 (4); 197-200.

D13. Eser B, Çetin M, Ünal A, **Coşkun HŞ,** Kayabaş Ü, Altınbas M. Ateşli nötropenik hastada ampirik tedavi yaklaşımı. Erciyes Tıp Dergisi. 2000, 22 (3): 155-162.

D14. Coşkun HŞ, Altınbas M, Er O, Eser B, Keklik M, Çetin M, Karahacıođlu E, Ünal A. Metastatik meme kanserinde vinorelbin ve doksorubisin kemoterapisinin etkinliđi. Türkiye Tıp Dergisi 2000; 7(4): 177-181.

D15. Er O, **Coşkun HŞ,** Soyuer I, Altınbas M. Late onset of distant metastases from breast cancer. Turkish Journal of Cancer 2001: 31 (3): 125-130.

D16. Coşkun HŞ, Er O, Uz AB, Karababa MA, Altınbas M, Küçük hücreli akciđer kanseri ve eritema multiforme: Olgu sunumu Erciyes Tıp Dergisi 2001; 23(2);79-82.

D17. Coşkun HŞ, Eser B, Çetin M, Er O, Ünal A, Altınbaş M, Karahacıođlu E, Kaplan B. Hodgkin's disease: Results Of Single Center in Central Anatolia. Turk J Haematol 2001; 18(2); 117-121.

D18. Coşkun HŞ, Er O, İlhan O. Multipl Myeloma: Güncel Yaklaşımlar. Erciyes Tıp Dergisi 2001: 23(2); 83-90.

D19. Coşkun HŞ, Arat M, Atahan Ş, Özdemir Kumbasar Ö, İlhan O, Koç H. İdiopatik pulmoner hemosiderozis: Bir olgu sunumu ve literatürün gözden geçirilmesi. Ankara Üniversitesi Tıp Fakültesi Mecmuası 2001; 54 (1): 77-81.

D20. Er O, **Coşkun HŞ,** Altınbas M, Eser B, Çetin M, Ünal A. Dukes B2 ve C kolorektal kanser hastalarının klinik özellikleri ve adjuvan kemoterapi sonuçları. Erciyes Üniversitesi 10 yıllık deneyimi. THOD 2001; 11(4): 210-216.

D21. Çetin M, Ünal A, Ekici M, Eser B, Kayabalı M, **Coşkun HŞ,** Altınbas M, Er O. Akciđer kanserlerinde hiperkoagulabilite ve hiperfibrinolizis. THOD 2001; 11 (4): 196-203.

D22. Coşkun HŞ, Er O, Altınbas M, Karahacıođlu E, Eser B. Ekstrapulmoner Küçük Hücreli Kanser: Tedavi ve Prognoz. TOD 2001; 16 (4): 191-193.

D23. Coşkun HŞ, Er O, Altınbas M, Akgün H, Ünal A. Memenin Yassı Hücreli Kanseri: Bir Olgu Sunumu. THOD 2002, 12 (1): 36-39.

D24. Er O, **Coşkun HŞ.** Altınbas M, Eser B, Çetin M, Ünal A. Kanserli hastalarda gelişen febril nötropeni ataklarında ampirik meropenem monoterapisinin değerlendirilmesi. Ankem Dergisi, 2002, 16(1): 18-21.

D25. Ünlühızcı K, Çolak R, Bayram F, Sözüer E, Öztürk F, Er O, **Coşkun HŞ,** Keleştimur F. The evaluation of clinical and hormonal parameters in the prediction of adrenocortical carcinoma. Is DHEAS level a reliable marker of adrenocortical carcinoma? Turkish Journal of Endocrinology and Metabolism 2002; 1:25-29.

D26. Coşkun HŞ, Er O, Altınbas M, Eser B, Özcan N, Çetin M, Ünal A. Subklavyen Ven Tıkanıklığı: Malign Mezotelyomada Nadir Bir Komplikasyon. Erciyes Tıp Dergisi 2002, 24(3): 144-148.

D27. Coşkun HŞ, Er O, Eser B, Çetin M, Altınbas M, Soyuer S, Karahacıođlu E, Ünal A. Erken Evre Hodgkin Hastalığı: Erciyes Üniversitesi Deneyimi. Erciyes Tıp Dergisi 2002, 24(3): 120-125.

D28. Arslan O, **Coşkun HŞ,** Arat M, Ender Soydan, Özcan M, Gürman G, Çelebi Ç, Demirer T, Akan H, İlhan O, Konuk N, Uysal A, Beksaç M, Koç H. The role of ABO incompatibility in allogeneic peripheral blood stem cell transplantation Turk J Haematol 2002, 19(3): 401-409.

D29. Coşkun HŞ, Er O, Fatih Tanrıverdi, Altınbaş M, Eser B, Ünal A, Çetin M. Metastatik mide kanserinin palyatif tedavisinde tek ajan fluorourasil, fluorourasil ve folinik asit kombinasyonu ve fluorourasil, adriamisin ve mitomisin (FAM) kombinasyonunun karşılaştırılması. Türkiye Tıp Dergisi 2002; 4: 145-151.

D30. Coşkun HŞ, Er O, Eser B, Çetin M, Serdar Şıvgın, Altınbaş M, Ünal A. Metastatik Malign Melanom Hastalarında Kemoimmunoterapi Sonuçları: Retrospektif Bir Analiz. Erciyes Tıp Dergisi 2002; 24(4): 174-179.

D31. Coşkun HŞ, Er O, Dr. Fatih Tanrıverdi, Altınbaş M, Eser B, Ünal A, Çetin M. Lokal İleri Evre Mide Kanserinde Palyatif Kemoterapi. Erciyes Tıp Dergisi 2003; 25(1):16-20

D32. Coşkun HŞ, Er O, Fatih Tanrıverdi, Altınbaş M. Hypereosinophilia as a Preclinical Sign of Tongue Squamous Cell Cancer in a Gastric Cancer Patient with Complete Remission. Turk J Haematol 2003; 20(2): 107-110.

D33. Özkan M, Er Ö, Kaplan B, **Coşkun HŞ**, Yıldız O, Altuntaş F, Eser B, Uçar K, Kurnaz F, Altınbaş M. Akciğerin malign tümörlerinde Vena kava superiyor gelişmesi kötü bir prognostik faktör mü? Türk Onkoloji dergisi 2003; 18(2): 60-63.

D34. Altuntaş A, Eser B, Kaplan B, Özlem Canöz, Kürşat Gündoğan, Ozkan M, Er O, **Coşkun HŞ**, Çetin M, Ünal A. Hodgkin hastalığında ilk basamak tedavi sonuçları: Tek merkez deneyimi. Türk Hematoloji Onkoloji Dergisi 2003; 13 (2): 79-86.

D35. Altınbaş M, Ozkan M, Er O, **Coşkun HŞ**, Kaplan B, Can Küçük, Altuntaş A, Eser B. Gemcitabine and cisplatin in the treatment of patients with locally advanced and metastatic pancreatic carcinoma. Turkish Journal of Cancer 2003; 33 (4): 181-186.

D36. Er O, **Coşkun HŞ**, Altınbaş M, Ozkan M, Eser B, Çetin M, Ünal A. İleri evre kolorektal kanserlerin tedavisinde Erciyes Üniversitesi sonuçları. Erciyes Tıp Dergisi 2003;25(3):144-149.

D37. Ozkan M, Er O, Kaplan B, Altınbaş M, **Coşkun HŞ**, Altuntaş A, Eser B, Karahacıoğlu E. Rezeke Edilemeyen Akciğer Adenokarsinomlarında Klinik Seyir. THOD 2003;4(13);212-217.

D38. Coşkun HŞ, Özlem Er. Trastuzumab. Hematoloji-Onkoloji 2004;6(3):130-137.

D39. Özlem Er, **Coşkun HŞ**, Metin Özkan, Olgun Kontaş, Işın Soyuer, Abdülhakim Coşkun, Ahmet Menkü, Mustafa Altınbaş. Yaygın hemorajik metastazlarla seyreden bir malign melanom olgusu. Erciyes Tıp Dergisi 2004;26 (2): 86-89

D40. Altınbaş M, Er O, **Coşkun HŞ**, Hakkı Doğan, Ozkan M, Kaynar L, Canöz O, Atabey F, Kula M. Malignant pleural mesothelioma with orbital metastases. Turkish Journal of Cancer 2005; 35(1): 35-37.

D41. Coşkun HŞ, Er O, Altınbaş M, Özkan M, Soyuer S. Serum Tumor Markers In Small Cell Lung Carcinoma Patients Treated With Cyclophosphamide, Epirubicine and Vincristine Combination. Turkish Journal of Cancer 2005; 35(2): 81-87.

D42. Aslan C, **Coşkun HŞ**. Thrombocytosis in Solid Tumors: Review of The Literature. Turkish J Haematology 2005; 22 (2): 59-64.

D43. Coşkun HŞ, Akbaş M, Şahin M, Alanoğlu G. Maksiller Sinüsün Küçük Hücreli Karsinomunda Orbita Tutulumu: Vaka Sunumu. THOD 2005; 15(2): 86-89.

D44.The evaluation of tumor markers in acute pancreatitis Erkan Cüre, Abdülkadir Baştürk, Mehmet Şahin, Medie Cumhuri Cüre, Hasan Şenol Coşkun, Mehmet İşler. Turkish Journal of Cancer 2007; 37(1): 11-15.

D45. Solid Tümörlü Hastalarda Kemoterapi İlişkili Anemi. **Hasan Şenol Coşkun**, Ozan Yılmaz, Osman Aydın, Güçhan Alanoğlu Mehmet Şahin Özlem Er, İnci Ergürhan İlhan. Türk Onkoloji Dergisi 2005; 20(2): 62-66

D46. Şirin Başpınar Nilgün kapucuoğlu, Nermin Karahan, Hasan Yasan, **Hasan Şenol Coşkun**, Özden Çandır. Breast carcinoma metastatic to nasopharynx Nazofarinkse metastaz yapmış meme karsinomu. Turkish Journal of Pathology 2006; 22(3):196-199.

D47. Coşkun HŞ, Çelebi Ç, Akan H. İmages in Hematology. Turkish Journal of Haematology 1999; 16(1): 39. (Erratum in Turkish Journal of Haematology 1999; 16(2): 99

D48- Dr. Şeyda GÜLENAY GÜNDÜZ, Dr. Hasan Şenol COŞKUN. Use of Molecular Diagnostics in Clinical Oncology: Head and Neck Cancers Türkiye Klinikleri J Med Oncol-Special Topics 2011;4(2):26-31

D49-Hasan Şenol COŞKUN. Editorials. Türkiye Klinikleri J Med Oncol-Special Topics 2012;5(2)

D50-Sema SEZGİN GÖKSU, Hasan ŞENOL COŞKUN. New Treatment Strategies in Breast Cancer. Türkiye Klinikleri J Med Oncol-Special Topics 2012;5(2):121-7

D51-Fatma Avcı Merdin, , Alparslan Merdin, Melek Karakurt Eryılmaz, Safiye Arık, Şeyda Gündüz, Hasan Şenol Coşkun, Hasan Altunbaş. Pituitary adrenal insufficiency in A cancer patient under opioid treatment. Nobel medicus 31; cilt 11, sayı: 1; 94-96

D52-Nuri Karadurmus ^{a,*}, Mehmet Ali Nahit Sendur ^b, Burcak Karaca^c, Omer Fatih Olmez^d, İlhan Hacibekiroglu ^e, Hasan Senol Coskun^f, Serkan Degirmencioglu ^g, Yasemin Kemal ^h, Saadettin Kilickapⁱ, Ahmet Taner Sumbul ^j, Burc Aydın^k, Hande Turna^l, Muhammet Ali Kaplan^m, Nalan Babacanⁿ, Umut Demirci ^o, Alper Ata^p, Dilek Erdem^q, Ahmet Ozet ^r, Huseyin Abali Experience from Turkish centers participating in the Early Access Program (EAP): Preliminary real-world safety data of nivolumab (nivo) combined with ipilimumab (ipi) in pre-treated advanced melanoma patients. Journal of Oncological Sciences 4 (2018) 125e129

D53: Erol Gürpınar, Hasan Şenol Coşkun, Yeşim Şenol, Cem Boneval, Mustafa Kemal Alimoğlu, Meral Gütekin. Mezuniyet Öncesi Tıp Eğitimi Programını Ulusal Çekirdek Eğitim Programına Göre Gözden Geçirme: Akdeniz Üniversitesi Tıp Fakültesi Deneyimi. Akd Tıp D / Akd Med J / 2015; 1: 12-24

D54. Meme Kanseri Bir Hastada Adjuvan Anastrozole Bağlı İrreversible Kalp Yetmezliği Fatma YALÇIN MÜSRİ, Hasan MUTLU, Melek KARAKURT ERYILMAZ, Derya KIVRAK SALİM, Hasan Şenol COŞKUN Akdeniz Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Tıbbi Onkoloji Bilim Dalı, Antalya, Türkiye
ATD 2017; 3: 211-213

D55: Kemoterapi Tedavisi Gören Kanser Hastalarının Cinsellik Algılarının ve Cinsel Bakım Gereksinimlerinin Belirlenmesi
Öznur KÖRÜKCÜ1, Fatma ARIKAN1, Ayşegül KÜÇÜKÇAKAL2, Hasan Şenol COŞKUN2
1Akdeniz Üniversitesi Hemşirelik Fakültesi, Antalya, Türkiye
2Akdeniz Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Tıbbi Onkoloji Bilim Dalı, Antalya, Türkiye
ATD 2018; 4: 025-034
DOI: 10.17954/amj.2018.101

D56: Parotis Bezinin Primer Malign Melanomu: Alışılmadık Primer Alan
Melek KARAKURT ERYILMAZ1, Hasan MUTLU1, Fatma YALÇIN MÜSRİ1, Derya KIVRAK SALİM1, Betül ÜNAL2, Gülsüm Özlem ELPEK2, Hasan Şenol ÇOSKUN1
1Akdeniz University School of Medicine, Department of Medical Oncology, Antalya, Turkey
2Akdeniz University School of Medicine, Department of Pathology, Antalya, Turkey
ATD 2018; 4: 063-066
DOI: 10.17954/amj.2018.116

D57: Kanser Hastalarına Bakım Verenlerin Sosyal Destek Düzeyleri ve Yaşam Kalitesi
Fatma ARIKAN1, Öznur KÖRÜKCÜ1, Mürvet ARTUK UÇAR2, Keziban ÖZCAN1, Sema SEZGİN GÖKSU3, Hasan Şenol COŞKUN3
1Akdeniz Üniversitesi Hemşirelik Fakültesi, Antalya, Türkiye
2Akdeniz Üniversitesi Hastanesi Gündüz Kemoterapi Ünitesi, Antalya, Türkiye
3Akdeniz Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Tıbbi Onkoloji Bilim Dalı, Antalya, Türkiye
ATD 2019; 5: 398-407
DOI: 10.17954/amj.2018.1128

D58: Renal Transplantasyon Sonrası Gelişen Solid Organ Kanserlerinin Kötü Sonlanımları: Tek Merkez Deneyimi
Derya KIVRAK SALİM1, Sema SEZGİN GÖKSU2, Hüseyin KOÇAK3, Hasan Şenol COŞKUN2
1Antalya Education and Research Hospital, Department of Medical Oncology, Antalya, Turkey
2Akdeniz University, School of Medicine, Department of Medical Oncology, Antalya, Turkey
3Akdeniz University, School of Medicine, Department of Nephrology, Antalya, Turkey
ATD 2021; 7: 036-044
DOI: 10.17954/amj.2021.2403

D59: İmmün Kontrol Noktası İnhibitörleri ile Tedavi Edilen Malign Melanom Hastalarında Antibiyotik ve Kortikosteroid Kullanımının Tedaviye Etkileri
Sema SEZGİN GÖKSU, Ali Murat TATLI, Gökhan KARAKAYA, Fatma YALÇIN MUSRİ, Mustafa Serkan ALEMDAR, Hasan Şenol COŞKUN
Akdeniz University Faculty of Medicine, Department of Medical Oncology, Antalya, Turkey
ATD 2021; 7: 045-051
DOI: 10.17954/amj.2021.2570

D60: Evre 3 Kolorektal Karsinom Tanılı Hastalarda Tümör Yerleşim Yerinin Nüks, Prognoz ve Sağ Kalım Üzerine Etkisi
Yusuf ILHAN, Sema SEZGIN GOKSU, Ali Murat TATLI, Gökhan KARAKAYA, Mustafa Serkan ALEMDAR, Fatma YALCIN MUSRI, Hasan Senol COSKUN
Akdeniz University Faculty of Medicine, Department of Medical Oncology, Antalya, Turkey
ATD 2021; 7: 071-076
DOI: 10.17954/amj.2021.2672

D61: KARAAGAÇ MUSTAFA, ARTAÇ MEHMET, SEZGIN GÖKSU SEMA, KARAKURT ERYILMAZ MELEK, COSKUN HASAN SENOL, BOZCUK HAKAN. Irinotecan and Ifosfamide Combination is an Effective and Safe Option in Patients with Refractory Small Cell Lung Cancer: A Retrospective Cross-Sectional Study. Eurasian Journal of Medicine and Oncology, 4(2), 172-176., Doi:10.14744/ejmo.2020.15578 (Yayın No: 6164855)

E. Ulusal bilimsel toplantılarda sunulan ve bildiri kitaplarında basılan bildiriler:

E1. Coşkun HŞ, Arslan O, Üstün C, Akan H. Amfoterisin B'nin nötropenik ateşin tedavisinde kullanımı. 8.Türk Klinik Mikrobiyoloji ve Enfeksiyon Hastalıkları Kongresi. 6-10 Ekim 1997, Antalya.

Daha çok abstrakt özet için hs.coskun@yahoo.com ile iletişime geçebilirsiniz.

F. Diğer yayınlar:

Türkçe Kitap Bölümü

F1. Şenol Coşkun, Özlem Er, Mustafa Altınbaş. 'Onkolojide Temel Yaklaşımlar' Klinik Tanıya Giriş, ed. Cengiz Utaş, Muhammet Güven, 230-236, Turgut Yayıncılık ve Ticaret A.Ş., İstanbul, 2002.

F2. Mustafa ALTINBAŞ, **H. Şenol COŞKUN**. Erkek Meme Kanserinde Hormonal Tedavi. In: Mustafa ALTINBAŞ (ed). Kanserde Hormon Tedavisi. Ankara, MN Medikal & Nobel Tıp Kitabevi 2009; pp: 341-351.

F3. Mustafa ALTINBAŞ, **H. Şenol COŞKUN**. Kanserde Takip: Erkek Meme Kanseri. Mustafa ALTINBAŞ (ed). Kanserde Hormon Tedavisi. Ankara, MN Medikal & Nobel Tıp Kitabevi 2009, p: 496.

İç Hastalıkları Uzmanlık Tez Özeti:

MULTİPLE MYELOMA HASTALARINDA SERUM TRANSFORMİNG GROWTH FAKTÖR BETA 1 SEVİYESİNİN KLİNİK İLE İLİŞKİSİ

Atmışaltı multiple myeloma (MM) hastasından elde edilen 82 serum örneğinde interlekin 6 (IL-6) ve transforming growth faktör beta 1 (TGF beta 1) çalışıldı. Örneklerin 41'i yeni tanı, 14'ü plato safhasındaki, 8'i tedaviye refrakter kalan ve 19'u ise tedavi sonrası nüks eden hastalara aitti. Hastaların medyan yaşı 59 (38-76) olarak bulundu. En sık olarak IgG tipi myelom (% 64.3) görüldü. Hastalardan 16'sında (%24.2) renal tutulum, 25'inde (%37.9) hiperkalsemi ve 54'ünde (%81.8) kemiklerde litik lezyonlar vardı.

Hastaların serum IL-6 ve TGF beta 1 düzeyleri belirlenen referans aralığına göre belirgin olarak yüksek saptandı. Korelasyon analizlerinde TGF beta 1 seviyesi ile beta 2 mikroglobulin (B2M) ve C reaktif protein (CRP) arasında ters yönde bir ilişki bulundu. Litik lezyonlar ve hiperkalsemi varlığı ile TGF beta 1 seviyesi arasında ilişki bulunamadı. Renal tutulumu olan hastalarda IL-6, CRP ve B2M düzeyleri yüksek bulunurken TGF beta 1 düzeyleri ve hemoglobilin miktarları düşük bulundu. Hastalarda tedavi sonrasında TGF beta 1 düzeylerinde anlamlı değişiklik olmadı. Buna karşılık yeni tanı alan hastalarda tedaviye iyi cevap veren grupta, tedaviye kötü cevap veren yada erken ölen hastalara göre tedavi öncesi B2M ve CRP düzeyleri düşük bulunurken TGF beta 1 düzeyleri anlamlı olarak yüksek tespit edildi.

Hastaların sağkalım analizlerinde TGF beta 1 seviyesini 700 ng/ml üzerinde olan hastaların, düşük olanlara göre anlamlı olarak daha uzun yaşam sürelerine sahip oldukları saptandı. IL-6 seviyesi 6 pg/ml üzerinde ve B2M seviyesi 1800 ng/ml üzerinde olan hastalar ise daha kısa yaşam sürelerine sahiptiler. TGF beta 1'in yüksek serum düzeyleri IL-6 ve B2M'e karşılık daha uzun yaşam süresinin bir göstergesi olmuştur.

Sonuçlar hematopoetik sistem için inhibitör ve düzenleyici görevi olan TGF beta 1'in MM'de oluşan proliferatif etkiyi dengelemek için arttığını düşündürmektedir. TGF beta 1 MM için iyi bir prognostik gösterge olabilir.

Tıbbi Onkoloji Yandal Uzmanlık Tez Özeti:

MEME KANSERİNDE HER2 ONKOPROTEİN EKSPRESYONU

Giriş: HER2 overekspresyonu meme kanserinde yaklaşık üçte bir oranında saptanmakta ve kötü prognozla beraber bulunmaktadır. HER2 overekspresyonu gösteren hastalarda hormonal tedaviye direnç olduğu yaygın kabul görmetedir. Bu hastaların CMF kombine kemoterapisine dirençli olduğu ve antarsiklin içeren şemalardan daha yüksek oranda fayda gördüğünü bildiren yayınlar vardır.

Materyal ve metod: Erciyes Üniversitesi Tıp Fakültesi'nde opere edilen 107 meme kanserinin patolojik bloklarına tekrar ulaşarak immuhistokimyasal olarak HER2 ekspresyonu değerlendirildi. Hastaların %87.9'u modifiye radikal mastektomi geçirmişti. Adjuvan tedavide hastaların %51.4'ü hormonoterapi, %76.6'sı radyoterapi ve %89.7 si kemoterapi almıştı. HER2 ekspresyonu hücresele boyanma göre sağkalıma katkısı değerlendirildi. özelliklerine göre negatif, 2+ ve 3+ olarak raporlandı. HER2 overekspresyonun sıklığı, klinik özelliklere göre dağılımı, sağkalım üzerine etkisi ve kemoterapinin HER2 ekspresyonuna

Sonuçlar: 107 meme kanseri çalışmaya alındı. Ortanca yaş 49, sınırlar 27 ve 76'ydı. Hastaların %48.6 sı premenopozal dönemdeydi. İnvaziv duktal karsinom tüm olguların %89.7'sini oluşturmuştu. HER2 32 hastada (%29.9) negatif, 41 hastada (38.3) 2+ ve 34 hastada (%31.8) 3+ bulundu. HER2 ekspresyonunun yaş, menapoz, histopatoloji, lenf nodu tutulumu, evre ve östrojen ve/veya progesteron reseptör pozitifliği yaşam süreleri daha düşük olmakla beraber istatistiksel anlamı yoktu. Antrasiklin açısından dağılımda fark yoktu. Takipleri sırasında 43 hastada (%40.2) nüks görüldü ve 21 hasta (%19.6) öldü. Nüks oranı, nüks bölgelerinin dağılımı ve ölüm oranı açısından HER2 ekspresyonuna göre fark bulunmadı. Hastaların tümünde 3 ve 5 yıllık hastaliksız yaşam oranları sırayla %67.1 ve %40.5, genel yaşam oranları ise sırayla %87.5 ve %66.1 olarak bulundu. HER2 3+ hastalarda diğerlerine göre yaşam oranları ve hesaplanan uygulanan hastalar CMF grubuna göre anlamlı olarak daha kötü prognoza sahipti. Kemoterapi kolları içerisinde HER2 3+ hastaların ve diğerlerinin dağılımı farksızdı. Kemoterapinin kendi grupları içerisinde HER2 3+ hastalar ve diğerlerinin yaşam oranları ve sürelerine etkisi bulunmadı. Sonuç: HER2 ekspresyonu 3+ hastalar için literatür'e benzer özellikte iken zayıf ve kuvvetli pozitifliklerin toplam oranı yüksek olarak bulunmuştur. HER2 3+ eksprese eden hastalarda daha düşük bir sağkalım süresi gözlenmiş fakat aradaki fark istatistiksel olarak anlamlı olmamıştır. Kemoterapinin gruplar arasında sağkalım açısından etkisi belirlenmemiştir. Daha homojen hasta gruplarında sağkalım ve kemoterapi etkisi yeniden değerlendirilmelidir.